ifosfamide has been researched along with mesna in 528 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 118 (22.35) | 18.7374 |
| 1990's | 241 (45.64) | 18.2507 |
| 2000's | 109 (20.64) | 29.6817 |
| 2010's | 54 (10.23) | 24.3611 |
| 2020's | 6 (1.14) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brock, N; Pohl, J; Stekar, J | 2 |
| Burkert, H; Fichtner, E; Schnitker, J | 1 |
| Brock, N; Niemeyer, U; Pohl, J; Scheffler, G; Stekar, J | 1 |
| Marti, C; Steiner, R; Viollier, AF | 1 |
| Fisher, C; Hawkins, RE; McKinna, JA; Schofield, JB; Wiltshaw, E | 1 |
| Faustini, M; Gianni, L; Nicolai, N; Piva, L; Pizzocaro, G; Salvioni, R | 1 |
| Dhingra, HH; Greenberg, J; Hong, WK; Lee, JS; Shirinian, M | 1 |
| Berendsen, HH; Haaxma-Reiche, H; Postmus, PE; Smit, EF | 1 |
| Bonfrer, JM; Jassem, E; Mooi, WJ; van Tinteren, H; van Zandwijk, N | 1 |
| Bischoff, H; Drings, P; Fischer, JR; Löchner, S; Manegold, C; Peukert, M; Schmähl, A | 1 |
| Cabanillas, F | 2 |
| Achterrath, W; Eiermann, W; Kuehnle, H; Meerpohl, HG | 1 |
| Burton, LC; Harper, PG; Lewis, LD; Rogers, HJ | 1 |
| Balcerzak, SP; Berenberg, JL; Keppen, MD; Metch, B; Militello, L; Pierce, HI; Zidar, BL | 1 |
| Einhorn, LH; Langefeld, C; Loehrer, PJ; Munshi, NC; Neuman, A; Nichols, CR; Roth, BJ; Sledge, G; Walsh, WB; Williams, SD | 1 |
| Chaitchik, S; Merimsky, O; Reider-Groswasser, I; Wigler, N | 1 |
| Goren, MP | 2 |
| Borden, EC; Falkson, CI; Falkson, G; Hayes, JA; Hunt, M; Smith, TJ | 1 |
| Frankel, EB | 1 |
| Barrett, RJ; Blessing, JA; McGehee, R; Sutton, GP | 1 |
| Cantwell, BM; Dawes, PJ; Hennessy, C; Lennard, TW; Millward, M; Sawan, A | 1 |
| Blomqvist, CP; Elomaa, I; Virolainen, M; Wiklund, TA | 1 |
| Anderson, J; Carey, RW; Case, DC; Gottlieb, A; Santarelli, MT | 1 |
| De Pascale, A; Errante, D; Foladore, S; Freschi, A; Frustaci, S; Lo Re, G; Monfardini, S; Sorio, R | 1 |
| Cantwell, BM; Hennessy, C; Lennard, TW; Millward, MJ | 1 |
| Bhargava, VL; Kumar, L | 1 |
| Brogden, RN; Dechant, KL; Faulds, D; Pilkington, T | 1 |
| Jakobsen, A; Mejlholm, I; Stornes, I | 1 |
| Almadrones, L; Hakes, T; Hoskins, W; Jones, W; Lewis, JL; Markman, M; Pizzuto, F; Reichman, B; Rubin, S | 1 |
| Dinh, TV; Doherty, MG; Hannigan, EV | 1 |
| Kredentser, DC | 1 |
| Becher, R; Höfeler, H; Kloke, O; May, D; Niederle, N; Richter, R; Scheulen, ME; Schmidt, CG; Wandl, U | 1 |
| Hausamen, TU; Loeffler, TM; Weber, FW | 1 |
| Brunner, KW; Cerny, T; Fey, MF; Goldhirsch, A; Joss, R; Küpfer, A; Martinelli, G; Terrier, F | 1 |
| Lind, MJ; Margison, JM; Radford, JA; Swindell, R; Thatcher, N; Wilkinson, PM | 1 |
| Araujo, CE; Brade, WP; Herdrich, K; Kachel-Fischer, U | 1 |
| Ayash, LJ; Critchlow, J; Deary, J; Eder, JP; Elias, AD; Hunt, M; Schnipper, L; Schryber, S; Weissman, L; Wheeler, C | 1 |
| Anderson, N; Bern, M; Lokich, I; Moore, C | 1 |
| Dorr, RT | 2 |
| Araujo, CE; Cerruti, R; Cervellino, JC; Francia, A; Pirisi, C | 1 |
| Araujo, CE; Callegari, J; Cervellino, JC; Pannunzio, O; Pirisi, C | 1 |
| Buckner, JC; Cascino, TL; Elliott, TE; Levitt, R; O'Fallon, JR; Scheithauer, BW | 1 |
| Barón, FJ; Buesa, JM; Esteban, E; Estrada, E; Fernández, R; Gracia, M; Lacave, AJ; Palacio, I | 1 |
| Fukuoka, M; Furuse, K; Ikegami, H; Kawahara, M; Kodama, N; Masuda, N; Nakamura, S; Negoro, S; Nishio, H; Ohnoshi, T | 1 |
| Brunner, K; Castiglione, M; Cerny, T; Küpfer, A; Lind, M; Martinelli, G | 1 |
| Lewis, LD; Meanwell, CA | 1 |
| Antman, KH; Begg, CB; Eder, JP; Elias, AD; Frei, E; Shea, T | 1 |
| Antman, KH; Elias, A | 1 |
| Goren, MP; Pratt, CB | 2 |
| Fujiwara, F; Imashuku, S; Iwasaku-Fujimoto, M; Morioka, Y; Todo, S | 1 |
| Dana, WJ; Schoenike, SE | 1 |
| Aisner, J; Antman, KH; Elias, A; Ryan, L | 1 |
| Antman, KH; Elias, A; Ryan, L | 1 |
| Cantwell, BM; Harris, AL; Millward, MJ | 1 |
| Hirosawa, A; Niitani, H; Shibuya, M | 1 |
| Baker, WJ; Fistel, SJ; Jones, RV; Weiss, RB | 1 |
| Araujo, CE; Brosto, M; Cervellino, JC; Pirisi, C; Rossi, R; Sanchez, O | 1 |
| Aalders, JG; de Vries, EG; Neijt, JP; ten Bokkel Huinink, WW; vd Burg, ME; vd Gaast, A; Willemse, PH | 1 |
| Berman, ML; Blessing, JA; Homesley, HD; Photopulos, G; Sutton, GP | 3 |
| Beauduin, M; Closon, MT; Focan, C; Majois, F; Michel, J; Paridaens, R; Piccart, M; Salamon, E; Tueni, E; Vindevoghel, A | 1 |
| Bickel, J; Drings, P; Kaufmann, M; Manegold, C; Schmid, H; Worst, P | 1 |
| Milla, A; Sanchiz, F | 1 |
| Hansen, HH; Hansen, M; Hansen, OP; Lund, B | 1 |
| Einhorn, LH; Loehrer, PJ; Munshi, N; Williams, SD | 1 |
| Biassoni, L; Canavese, G; Coialbu, T; Folco, U; Gatti, C; Giacchero, A; Rosso, R; Toma, S | 1 |
| Kasai, H; Matsui, S; Muraoka, Y; Nara, H; Watanabe, H | 1 |
| Berger, H; Boehm, E; Denecke, H; Issels, RD; Jauch, KW; Nagele, A; Peter, K; Prenninger, SW; Sauer, H; Wilmanns, W | 1 |
| Orel, NF; Perevodchikova, NI; Trofimova, NV | 1 |
| Iqbal, Z; Mallick, JA; Zaidi, SH | 1 |
| Brunner, KW; Cerny, T; Küpfer, A; Zeugin, T | 1 |
| Azab, M; Droz, JP; Ghosn, M; Mahjoubi, M; Theodore, C | 1 |
| Dietel, M; Hossfeld, DK; Schwarz, R; Weh, HJ; Wingberg, D; Zornig, C; Zügel, M | 1 |
| Cantwell, BM; Gane, A; Hall, G; Huang, M; Lind, MJ; Moore, A; Roberts, JT | 1 |
| Hamaguchi, K; Komai, K; Nagasue, N; Nishida, T; Okura, N; Sakihama, H; Yakushiji, M | 1 |
| Blackledge, G; Dombernowsky, P; Mouridsen, HT; Santoro, A; Schütte, J; Somers, R; Stewart, W; Thomas, D; van Oosterom, AT; Verweij, J | 1 |
| Alberts, AS; Falkson, G; van Zyl, L | 2 |
| Dubbelman, R; Franklin, H; McVie, JG; Simonetti, G; ten Bokkel Huinink, WW; van Tinteren, H; van Zandwijk, N; Wanders, J | 1 |
| Dhingra, HM; Glisson, BS; Holoye, PY; Hong, WK; Jeffries, D; Lee, JS; Levy, JK; Murphy, WK; Raber, MN; Umsawasdi, T | 1 |
| Halligan, AW; McGuinness, EP | 1 |
| Chasen, MR; Falkson, G; Falkson, HC | 1 |
| Brittinger, G; Engelhard, M; Gerhartz, H; Heinz, R; Huhn, D; Meusers, P; Neubauer, A; Siegert, W; Stacher, A; Thiel, E | 1 |
| Atherton, P; Buxton, J; Honigsberger, L; Mould, J | 1 |
| Alton, NK; Bronchud, M; Crowther, D; Dexter, TM; Scarffe, JH; Souza, LM; Testa, NG; Thatcher, N | 1 |
| Brittinger, G; Engelhard, M; Gerhartz, HH; Heinz, R; Huhn, D; Meusers, P; Siegert, W; Stacher, A; Thiel, E; Wilmanns, W | 1 |
| Brock, N | 2 |
| Antman, KH; Elias, A; Grier, HE; Ryan, L; Sherman, D | 1 |
| Boossy, J; Claessens, JJ; Focan, C; Focan-Henrard, D; Reginster, M | 1 |
| Douglass, EC; Etcubanas, E; Goren, MP; Green, AA; Hayes, FA; Horowitz, ME; Meyer, WH; Pratt, CB; Thompson, EI; Wilimas, JA | 1 |
| Becher, R; Höfeler, H; Kloke, O; Kurschel, E; Schilcher, RB; Schmidt, CG; Wandl, U; Weinhardt, O | 1 |
| de Jong, PE; Elema, JD; Mulder, NH; Willemse, PH | 1 |
| de Vries, EG; Willemse, PH | 1 |
| Buckner, JC; Edmonson, JH; Long, HJ; Loprinzi, CL; Schaid, DJ | 1 |
| Alberts, AS; Ansell, SM; Falkson, G | 1 |
| Cantwell, BM; Carmichael, J; Harris, AL | 1 |
| Cantwell, BM; Carmichael, J; Harris, AL; Mannix, KA | 1 |
| Angueyra, N; Schwartzman, E; Scopinaro, M | 1 |
| Baurain, R; Cornu, G; de Kraker, J; Ferster, A; Ninane, J; Trouet, A | 1 |
| Douglass, EC; Etcubanas, EL; Goren, MP; Green, AA; Hayes, FA; Horowitz, ME; Meyer, WH; Pratt, CB; Thompson, EI; Wilimas, JA | 1 |
| Exner, U; Göbel, U; Jürgens, H; Kühl, J; Ritter, J; Treuner, J; Weinel, P; Winkler, K | 1 |
| Craft, AW; Davies, SM; Pearson, AD | 1 |
| Aisner, J; Antman, KH; Collins, J; Elias, A; Ryan, L; Sulkes, A | 1 |
| Hilgard, P; Pohl, J; Stekar, J | 1 |
| Falkson, CI; Falkson, G; Falkson, HC | 1 |
| Berman, ML; Blessing, JA; Homesley, HD; Malfetano, J; Sutton, GP | 1 |
| Dodge, RK; Goren, MP; Meyer, WH; Pratt, CB; Viar, MJ; Wright, RK | 1 |
| Adcock, L; Blessing, JA; DeEulis, T; Sutton, GP; Webster, KD | 1 |
| Castel, V; Esquembre, C; Fernandez, JM; Ferris, J; Ruiz, JG; Verdeguer, A | 1 |
| Chetiyawardana, SD; Cullen, MH; Joshi, RC; Woodroffe, CM | 1 |
| Tournade, MF | 1 |
| Blessing, JA; DiSaia, PJ; Photopulos, G; Rosenshein, N; Sutton, GP | 1 |
| Cerny, T; Lind, MJ; Margison, JM; Thatcher, N; Wilkinson, PM | 1 |
| Goren, MP; Pratt, CB; Viar, MJ | 1 |
| Anderson, H; Barber, PV; Barnes, P; Cerny, T; Deiraniya, A; Stout, R; Thatcher, N; Wolstenholme, RJ | 1 |
| Bozzino, JM; Cantwell, BM; Corris, P; Harris, AL | 1 |
| Arriagada, R; Baldeyrou, P; Droz, JP; le Chevalier, T; Pastran, Z; Rouesse, J; Spielmann, M | 1 |
| Lange, OF | 1 |
| Blackledge, G; Blake, AE; Blake, DR; Honigsberger, L; Latief, TN; Meanwell, CA; Mould, JJ; Shaw, IC; Spooner, D; Williams, AC | 1 |
| Cantwell, BM; Harris, AL | 1 |
| Blackledge, G; Kelly, KA; Meanwell, CA | 1 |
| Harrop, JS; Hill, PG | 1 |
| Blackledge, G; Constantine, G; Meanwell, C | 1 |
| Goren, MP; Horowitz, ME; Pratt, CB; Wright, RK | 1 |
| Perren, TJ; Smith, IE; Turner, RC | 1 |
| McCallum, AK | 1 |
| Husband, DJ; Watkin, SW | 1 |
| Brock, N; Dietrich, I; Hilgard, P; Manz, I; Niemeyer, U; Pohl, J; Przybylski, M | 1 |
| Beuzeboc, P; Dorval, T; Garcia-Giralt, E; Jouve, M; Livartowski, A; Palangie, T; Pouillart, P; Scholl, S | 1 |
| Höfeler, H; Höffken, K; Kath, R; Müller, M; Niederle, N; Schmidt, CG; Schoetensack, B; Wandl, U | 1 |
| Bozzino, JM; Cantwell, BM; Harris, AL | 1 |
| Anderson, H; Hilton, A; Rahman, A; Smith, DB; Steward, WP; Thatcher, N; Webb, K | 1 |
| Barón, MG; Girón, CG; Jalón, JI; Ordónez, A | 1 |
| Cantwell, BM; Harris, AL; Pooley, J | 1 |
| Antman, KH; Elias, AD | 1 |
| Blackledge, G; Chetiyawardana, AD; Kavanagh, J; Latief, TN; Lawton, FG; Meanwell, CA; Mould, JJ; Spooner, D; Stuart, NS | 1 |
| Douglass, E; Etcubanas, E; Green, AA; Hayes, FA; Horowitz, ME; Igarashi, M; Meyer, WH; Pratt, CB; Thompson, E; Wilimas, J | 1 |
| Eguchi, K; Jett, JR; Saijo, N; Sakurai, M; Sano, T; Sasaki, Y; Shinkai, T; Suemasu, K; Tamura, T | 1 |
| Blackledge, G; Blake, AE; Honigsberger, L; Kelly, KA; Meanwell, CA | 1 |
| Cornille, H; Delépine, G; Delépine, N; Desbois, JG; Jasmin, C; Taillard, F | 1 |
| Douglass, EC; Etcubanas, E; Green, AA; Hayes, FA; Horowitz, ME; Meyer, WH; Pratt, CB; Thompson, EI; Wilimas, JA | 1 |
| Fisher, C; Harmer, C; McKinna, A; Westbury, G; Wiltshaw, E | 1 |
| Blackledge, G; Bramwell, VH; Mouridsen, HT; Santoro, A; Somers, R; Sylvester, R; Thomas, D; Van Oosterom, A | 1 |
| Gasparini, M | 1 |
| Christian, E; Coerper, C; Dias Wickramanayake, P; Klein, HO | 1 |
| Gad-el-Mawla, N | 1 |
| Andriole, GL; Arasi, V; Linehan, M; Magrath, IT; Miser, JS; Sandlund, JT | 1 |
| Cheng, E; Dougherty, J; Kemeny, N; Lipperman, R; Reichman, B | 1 |
| Brock, N; Pohl, J | 1 |
| Forquer, R; Jarosinski, P; Kinsella, TJ; Magrath, I; Miser, JS; Triche, TJ; Tsokos, M; Wesley, R | 1 |
| Akatchereian, C; Flamant, F; Ghosn, M; Salloum, E; Taleb, N | 1 |
| De Forges, A; Droz, JP; Ghosn, M; Theodore, C | 1 |
| Cantwell, BM; Carmichael, J; Ghani, S; Harris, AL | 1 |
| Brock, N; Guan, ZZ; He, YJ; Li, GC; Li, JQ | 2 |
| Anderson, J; Case, DC; Ervin, TJ; Gottlieb, A | 1 |
| Carde, P; Droz, JP; Flamant, F; Friedman, S; Ghosn, M; Hayat, M; Leclerq, B | 1 |
| Baume, D; Droz, JP; Ghosn, M; Kramar, A; Moran, A; Ostronoff, M; Pico, JL; Salloum, E; Spielmann, M; Theodore, C | 1 |
| Nagasue, N; Nishida, T | 1 |
| Abbruzzese, JL; Ajani, JA; Boman, BM; Faintuch, JS; Goudeau, P; Levin, B; Nicaise, C; Yeomans, AC | 1 |
| Brade, WP; Dittrich, C; Herold, C; Keller, A; Mader, R; Moser, K; Schlappack, O; Steger, GG | 1 |
| Antman, KH; Montella, D; Rosenbaum, C; Schwen, M | 1 |
| Bryant, BM; Ford, HT; Jarman, M; Smith, IE | 1 |
| Rose, JW; Shaw, IC | 1 |
| Adams, P; Bradford, E; Haines-Nutt, RP; Jakobson, K; Rowland, CG | 1 |
| Araujo, CE; Tessler, J | 1 |
| Göbel, D; Matthiessen, W; Stempinski, E; Thalmann, U | 1 |
| Harper, PG; Kaye, SB; Stuart-Harris, R; Wiltshaw, E | 1 |
| de Kraker, J; Voûte, PA | 1 |
| Brock, N; Christian, E; Coerper, C; Klein, HO; Pohl, J; Wickramanayake, PD | 1 |
| Burkert, H | 1 |
| Brade, W; Herdrich, K; Hilgard, P | 1 |
| Christian, E; Coerper, C; Graf, L; Klein, HO; Wickramanayake, PD | 1 |
| Bremer, K; Niederle, N; Scheulen, ME; Schütte, J; Seeber, S | 1 |
| Gowing, NF; Harper, PG; Kaye, SB; Mooney, CA; Parsons, CA; Stuart-Harris, RC; Wiltshaw, E | 1 |
| Calman, KC; Dalton, JF; Kaye, SB; Sangster, G | 1 |
| Christian, E; Coerper, C; Klein, HO; Wickramanayake, PD | 1 |
| Burkert, H; Hilgard, P | 1 |
| Brema, F; Cinquegrana, A; Nobile, MT; Rosso, R; Santi, L | 1 |
| Breuel, HP; Burkert, H; Lücker, PW; Wetzelsberger, N | 1 |
| Czownicki, Z; Utracka-Hutka, B | 1 |
| Brock, N; Stekar, J | 1 |
| Falkson, G; Falkson, HC; Stapelberg, R; Van Dyk, JJ | 1 |
| Brock, N; Pohl, J; Scheef, W; Stekar, J | 1 |
| Demetri, GD; Elias, AD | 1 |
| Akbulut, H; Arican, A; Cay, F; Demirkazik, A; Dinçol, D; Içli, F; Karaoğuz, H | 1 |
| Bessell, EM; Chan, SY; Dobbs, SP; Gribbin, C | 1 |
| Ansorge, S; Brandis, M; Mohrmann, M; Schönfeld, B | 1 |
| Chiang, Y; Cowan, KH; Dunbar, CE; Goldspiel, B; Kohler, D; McDonagh, KT; Nienhuis, AW; O'Shaughnessy, JA; Sorrentino, BP; Wilson, W | 1 |
| Calvert, AH; Cantwell, BM; Chapman, F; Gumbrell, L; Lind, MJ; McCann, E; Middleton, I; Millward, MJ; Proctor, M; Simmonds, D | 1 |
| Cabanillas, F; Cortes, JE; Kurzrock, R; Seymour, JF; Talpaz, M | 1 |
| Bumma, C; Comandone, A; Oliva, C; Palumbo, R; Rosso, R; Toma, S; Vincenti, M | 1 |
| Antoine, E; Brain, E; Fontaine, F; Genin, J; Janin, N; Kayitalire, L; Le Cesne, A; Le Chevalier, T; Spielmann, M; Toussaint, C | 1 |
| Skinner, R | 1 |
| Bretti, S; Bumma, C; Bussi, P; Comandone, A; Goffredo, F; Leone, L; Oliva, C | 1 |
| Bonichon, F; Bui, BN; Chevallier, B; Chevreau, C; Cupissol, D; Fargeot, P; Krakowski, I; Maugard-Louboutin, C; Peny, AM; Thyss, A | 1 |
| de Campos, E; Dougal, M; Milroy, R; Radford, J; Steward, W; Swindell, R; Testa, N; Thatcher, N | 1 |
| Cabanillas, FC; Hagemeister, FB; McLaughlin, P; Rodriguez, MA; Romaguera, JE; Swan, F; Velasquez, W | 2 |
| Grant, SC; Heelan, RT; Kris, MG; Miller, VA; Pfister, DG; Pisters, KM; Rigas, JR | 1 |
| Greenberg, S; Patsner, B | 1 |
| Araujo, CE; Cervellino, JC; Miles, H; Nishihama, A; Sánchez, O | 1 |
| Allenbacher, A; Botzler, C; Issels, RD; Meier, T; Multhoff, G; Wiesnet, M; Wilmanns, W | 1 |
| Crooks, GM; Sato, JK | 1 |
| Kawaguchi, N; Kuroda, H; Manabe, J; Matsumoto, S; Shimoji, T | 1 |
| Bertelsen, K; Pfeiffer, P; Sørensen, P | 1 |
| Farisse, P; Somma-Mauvais, H; Viallat, JR | 1 |
| Herman, RL; Kelley, AS; Muggia, FM; Russell, CA; Spicer, DV; Turrill, M | 1 |
| Anelli, A; Cruz, SM; Epelman, S; Gorender, EF; Katz, A; Marques, LA; Oliveira, RM | 1 |
| Azorin, JF; Delepine, G; Delepine, N; Destable, MD; Pocard, M; Tremblay, B | 1 |
| Cabanillas, F; Hagemeister, FB; Hill, D; McLaughlin, P; Moore, DF; Rodriguez, MA; Romaguera, JE; Sarris, AH; Swan, F; Younes, A | 1 |
| Allenbacher, A; Botzler, C; Issels, R; Meier, T; Mueller, E; Multhoff, G; Wiesnet, M | 1 |
| Asbury, R; Boros, L; Chang, AY; Hsieh, RK | 1 |
| Cerny, T; Hartmann, B; Junker, E; Küpfer, A; Lauterburg, BH; Nguyen, T | 1 |
| Corthouts, B; Dirix, LY; Prové, A; Schrijvers, D; van Marck, E; van Meerbeeck, J; van Oosterom, AT; Vermeire, P | 1 |
| Cabanillas, F; Rodriguez, MA | 1 |
| Fleming, ID; Meyer, WH; Parham, DM; Pratt, CB; Rao, BN | 1 |
| Rosen, G | 1 |
| Adcock, L; Blessing, JA; Homesley, HD; McGuire, WP; Sutton, GP | 1 |
| Boal, JH; Engel, J; Ho, CK; Ludeman, SM; Niemeyer, U | 1 |
| Eckardt, J; Eilber, F; Forscher, C; Fu, YS; Holmes, C; Lowenbraun, S; Rosen, G | 1 |
| Blessing, JA; Homesley, HD; Malfetano, JH; Sutton, GP | 1 |
| Bokemeyer, C; Casper, J; Dunn, T; Harstrick, A; Ludwig, E; Schmoll, HJ | 1 |
| Cooper, CS; Fisher, C; Fletcher, CD; Gill, S; Grimer, R; Gusterson, BA; Jayatilake, H; Law, MG; Patterson, H; Thomas, M | 1 |
| Chastang, C; Depierre, A; Jacoulet, P; Janicot, H; Lebeau, B; Lombard, JN; Milleron, B; Moro, D; Paillot, N; Quoix, E | 1 |
| Hamdan, H; Skubitz, KM; Thompson, RC | 1 |
| Sutton, G | 1 |
| Lynch, MP; Ruland, T | 1 |
| Issels, RD; Meier, TH; Müller, E; Multhoff, G; Wilmanns, W | 1 |
| Antman, K; Balcerzak, SP; Barlogie, B; Cooper, RM; Crowley, J; Elias, A; Natale, RB; Rivkin, SE; Trump, DL; Weiss, GR | 1 |
| Cerny, T | 1 |
| Bell, B; Bernstein, ML; Buchanan, GR; Devine, S; Dreyer, Z; Grier, H; Krischer, J; Kung, F; Land, V; Whitehead, VM | 1 |
| Abdel-Rahman, S; Bosse, D; Issels, RD; Jauch, KW; Schildberg, FW; Starck, M; Wilmanns, W | 1 |
| Kirkpatrick, A; Postmus, PE; Smit, EF; Splinter, TA | 1 |
| Cornelius, AS; Murry, DJ; Teresi, ME | 1 |
| Cullen, MH | 1 |
| Cassidy, J; Kaye, SB | 1 |
| DiFino, S; Duggan, DB; Graziano, SL; Green, MR; Herndon, JE; Modeas, C; Richards, F | 1 |
| Focan, C; Kreutz, F; Levi, F | 1 |
| Apfel, R; Bogdahn, U; Dekant, A; Jäger, AH; Pfeufer, B | 1 |
| Craft, AW; Pearson, AD; Sharkey, IM; Skinner, R | 1 |
| Almenarez, J; Casado, A; Diaz-Rubio, E; Dominguez, S; González Larriba, JL; López-Vega, JM; Martín, M; Sastre, J | 1 |
| Benjamin, RS; Legha, SS; Nicaise, C; Patel, SR | 1 |
| Bell, DR; Dalley, D; Levi, J; Simes, RJ; Stuart-Harris, R; Wiltshaw, E | 1 |
| Kellner, R; Schütte, J; Seeber, S | 1 |
| Blessing, JA; Look, KY; McGuire, WP; Patton, T; Sutton, GP | 1 |
| Baker, TR; Hempling, RE; Piver, MS | 1 |
| Blessing, JA; DiSaia, PJ; McGuire, WP; Sutton, GP | 1 |
| Avery, L; Bowman, L; Douglass, EC; Marina, N; Meyer, WH; Ochs, J; Pratt, CB; Thompson, EI; Wilimas, J | 1 |
| Avery, L; Douglass, EC; Heideman, R; Kellie, SJ; Kovnar, EH; Kun, L; Pratt, CB | 1 |
| Hartmann, LC; Ingle, JN; Krook, JE; Mailliard, JA; Wieand, HS | 1 |
| Gurney, H; Harnett, P; Kefford, R; Stuart-Harris, R | 1 |
| Falk, M; Fridrik, MA; Haidinger, R; Hausmaninger, H; Klocker, J; Linkesch, W; Neubauer, M; Pont, J; Radaszkiewicz, T; Raudaschl, G; Schiller, L; Seewann, HL; Sill, H; Stöger, M | 1 |
| Arroyo, A; Castaldi, J; Cuevas, MA; Ferreyra, R; Focaccia, G; Lacava, J; Leone, B; Machiavelli, M; Perez, J; Rabinovich, M; Romero, A; Suttora, G; Vallejo, C | 1 |
| Barişta, I; Firat, D; Güllü, I; Tekuzman, G | 1 |
| Alkiş, N; Baltali, E; Barişta, I; Celik, I; Güler, N; Güllü, I; Kars, A; Tekuzman, G; Yalçin, S; Zengin, N | 1 |
| Colucci, G; Galetta, D; Gebbia, N; Gebbia, V; Majello, E; Valenza, R | 1 |
| Acito, L; Angiona, S; Bella, M; Carlini, P; Di Costanzo, F; Donati, D; Maggian, P; Mazzocchi, B; Tagliaventi, M; Zironi, S | 1 |
| Atlante, G; Calabresi, F; Della Giulia, M; Iacovelli, A; Marolla, P; Nardi, M; Pollera, CF; Ruggeri, EM | 1 |
| Blessing, JA; DiSaia, PJ; Park, R; Rosenshein, N; Sutton, G | 1 |
| Drinkard, LC; Golomb, HM; Hoffman, PC; Krauss, SA; Masters, GA; Samuels, BL; Vokes, EE | 1 |
| Budd, GT; Connelly, EF | 1 |
| Johnson, DH | 1 |
| Palackdharry, CS | 1 |
| Pratt, CB | 1 |
| Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K | 1 |
| Brannon, W; Crawford, ED; Eisenberger, MA; O'Rourke, MA; Williamson, SK; Wolf, MK | 1 |
| Benner, SE; Dimery, IW; Dunnington, JS; Hong, WK; Huber, MH; Lippman, SM; Shirinian, M | 1 |
| Bezwoda, WR; Fried, J; Ruff, P; Stein, ME; Weaving, A | 1 |
| Bui, NB; Coindre, JM; Kantor, G; Kind, M; Stöckle, E; Thomas, L | 1 |
| Amenta, P; Drachtman, RA; Ettinger, LJ; Han, P | 1 |
| Brunetti, JC; Fountain, KS; Hibshoosh, H; Neugut, AI; Rubin, M; Wahid, NA | 1 |
| Avery, L; Fang, L; Furman, WL; Luo, X; Marina, N; Pratt, CB | 1 |
| Clamon, G; Crawford, J; Graziano, SL; Green, MR; Herndon, JE; Rege, VB; Richards, F; Valone, FH | 1 |
| Baltali, E; Barista, I; Benekli, M; Celik, I; Firat, D; Güler, N; Güllü, IH; Kars, A; Kiraz, S; Tekuzman, G | 1 |
| Ahn, C; Doroshow, JH; Hamasaki, V; Leong, L; Margolin, K; Morgan, R; Raschko, J; Shibata, S; Somlo, G; Tetef, M | 1 |
| Bachmann, P; Dolensky, J; Drings, P; Giaccone, G; Jackevicius, A; Lentz, MA; Manegold, C; Pawinski, A; Petruzelka, L; Schnaars, Y; Skacel, Z; van Glabbeke, M; van Zandwijk, N; Zatloukal, P | 1 |
| Blessing, JA; Burke, TW; DeMars, LR; Grendys, EC; Moore, D; Sutton, GP | 1 |
| Abu Rabia, A; el-Attar, I; el-Said, A; Gaafar, R; Gad el-Mawla, N; Hamza, MR; Khaled, HM; Magrath, I | 1 |
| Chao, EY; Donehower, RC; Frassica, FJ; Ikeda, K; Inoue, N; Tomita, K | 1 |
| Burghouts, JT; Curran, D; Giaccone, G; Gozzelino, F; Groen, HJ; Kirkpatrick, A; Postmus, PE; Sahmoud, T; Scagliotti, G; Splinter, TA | 1 |
| Amato, S; Barbieri, M; Cuevas, M; Dominguez, M; Lacava, J; Langhi, M; Leone, B; Machiavelli, M; Ortiz, E; Perez, J; Rodriguez, R; Romero Acuña, J; Romero Acuña, L; Romero, A; Sabatini, C; Salvadori, M; Vallejo, C | 1 |
| Balcerzak, SP; Hicks, LG; Zalupski, M | 1 |
| Rodriguez, MA | 1 |
| Kurowski, V; Wagner, T | 1 |
| Konarski, L; Kowalski, P; Kuśnierczyk, H; Radzikowski, C | 1 |
| Benjamin, RS; Burgess, MA; Hays, C; Papadopolous, N; Patel, SR; Plager, C; Vadhan-Raj, S | 1 |
| Rossi, R | 1 |
| Barişta, I; Başçil, N; Celik, I; Güllü, IH; Kars, A; Tekuzman, G; Yalçin, S | 1 |
| Goodman, TL; Goren, MP; McKenna, LM | 1 |
| Edmonson, JH; Grill, JP; Kvols, LK; Long, HJ; Mann, BS | 1 |
| Cabanillas, F; Rodriguez-Monge, EJ | 1 |
| Chap, LI; Ippolito, V; Mirra, J; Rentschler, R; Rosen, P | 1 |
| Pensa, F; Pronzato, P; Tani, F; Vaira, F; Vanoli, M; Vigani, A | 1 |
| Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T; Yonemoto, T | 1 |
| Albera, C; Bèguelin, R; Cacchione, R; Campestri, R; Dragosky, M; Dupont, J; Fernández, J; Garay, G; Nicastro, M; Noviello, V; Nucifora, E; Riveros, D; Schnidrig, P; Triguboff, E | 1 |
| Akan, H; Aydogdu, I; Beksac, M; Gurman, G; Ilhan, O; Koc, H; Konuk, N; Ozerol, E; Uysal, A | 1 |
| Casanova, L; Otero, JC; Rodriguez, W; Solidoro, A; Vallejos, C | 1 |
| Fisher, C; Harmer, CL; Judson, IR; Thomas, JM; Verrill, MW; Wiltshaw, E | 1 |
| Antimi, M; Gatti, C; Palmeri, S; Palumbo, R; Raffo, P; Toma, S; Villani, G | 1 |
| Berkowitz, R; Bunnell, CA; Buswell, L; Muto, M; Sheets, E; Shulman, LN; Thompson, L | 1 |
| Anthony, LB; Brade, WP; Bush, DA; Frazier, MW; Goren, MP; Hande, KR; Johnson, DH; Li, JT | 1 |
| Antman, K; Baker, LH; Balcerzak, SP; Clamon, GH; Crowley, J; Kempf, RA; Weiss, RB | 1 |
| Hsu, WL; Jen, YM; Liu, HS; Shueng, PW; Wu, CJ | 1 |
| Moore, MJ; Siu, LL | 1 |
| Losardo, P; Pensa, F; Pronzato, P; Tognoni, A | 1 |
| Buckner, JC; Lewis, JE; McElroy, EA | 1 |
| Antman, KH; Ayash, LJ; Coleman, N; Elias, AD; Frei, E; Ibrahim, J; McCauley, M; Mills, L; Schnipper, L; Schwartz, G; Teicher, BA; Warren, D; Wheeler, C | 1 |
| Cabanillas, F; Dong, K; Hagemeister, FB; McLaughlin, P; Moon, T; Rodriguez, MA; Rodriguez-Diaz Pavón, J; Romaguera, JE | 1 |
| Boyages, J; Gurney, H; Harnett, P; Kefford, R | 1 |
| Advani, SH | 1 |
| Biesma, B; Cox, A; Festen, J; Postmus, PE; Splinter, TA; Tjan-Heijnen, VC; Wagener, DJ | 1 |
| Esparza-Guerra, L; Holmes, FA; Hortobagyi, GN; Valero, V; Walters, RS | 1 |
| Barişta, I; Celik, I; Firat, D; Güler, N; Hayran, M; Kars, A; Ozyilkan, O; Tekuzman, G | 1 |
| Aeschlimann, C; Cerny, T; Küpfer, A; Schefer, H | 1 |
| McDonald, AR; Pogrel, MA; Sharma, A | 1 |
| Aapro, MS; De Braud, F; De Pas, T; Fazio, N; Goldhirsch, A; Munzone, E; Nolè, F; Orlando, L; Zampino, MG | 1 |
| Foxall, PJ; Hartley, JM; Lapsley, M; Neild, GH; Nicholson, JK; Singer, JM; Souhami, RL | 1 |
| Adam, Z; Hájek, R; Hejlová, N; Klabusay, M; Korístek, Z; Krahulcová, E; Král, Z; Mayer, J; Müllerová, I; Navrátil, M; Penka, M; Tomíska, M; Vásová, I; Vodvárka, P; Vorlícek, J | 1 |
| Cormio, G; Di Gesù, G; Di Vagno, G; Loverro, G; Melilli, GA; Selvaggi, L | 1 |
| Enneking, WF; Lindner, NJ; Scarborough, MT; Spanier, SS | 1 |
| Cuomo, AM; Pavesi, L; Poggi, G; Preti, P; Robustelli della Cuna, FS; Zambelli, A | 1 |
| Bachier, C; Cabanillas, F; Hagemeister, FB; McLaughlin, P; Preti, H; Rodriguez, MA; Romaguera, JE; Sarris, AH; Weber, D; Younes, A | 1 |
| Craffey, M; Dowlati, A; Levitan, N; MacKay, W; McKenney, J; Remick, SC; Tahsildar, H | 1 |
| Abdallah, A; Bastert, G; Egerer, G; Fersis, N; Funk, L; Goldschmidt, H; Haas, R; Hahn, U; Hohaus, S; Kaul, S; Martin, S; Schlenk, RF; Schneeweiss, A; Wallwiener, D | 1 |
| Baerlocher, GM; Beer, JH; Cerny, T; Meiselman, HJ; Owen, GR; Reinhart, WH | 1 |
| Christodoulou, K; Giannakopoulos, K; Giannikos, L; Kalahanis, N; Katsilambros, N; Kosmas, C; Papadopoulos, O; Petrikos, G; Polyzos, A; Tsavaris, N; Veslemes, M | 1 |
| Czyzewski, EA; Goldman, S; Hallahan, DE; Mundt, AJ; Nachman, J; Rubin, C | 1 |
| Cojean-Zelek, I; Le Cesne, A; Le Chevalier, T; Lepechoux, C; Merimsky, O; Mesurolle, B; Missenard, G | 1 |
| Bui, BN; Chevallier, B; Chevreau, C; Coindre, JM; Cour-Chabernaud, V; Gil, B; Krakowski, I; Maugard, C; Mihura, J | 1 |
| Jockenhövel, F; Kummer, G; Mann, K; Philipp, T; Reinhardt, W; Reinwein, D; Sauter, V; Uppenkamp, M; Witzke, O | 1 |
| Bancalari, L; Cadenotti, L; Canessa, PA; Cordani, S; Maggiani, R; Pensa, F; Pronzato, P; Tognoni, A; Vaira, F; Vigani, A | 1 |
| Chan, K; Davies, S; Lu, H; Springate, J; Taub, M | 1 |
| Felgenhauer, J; Hawkins, D; Radich, J; Thomson, B | 1 |
| Bauman, NM; Callaghan, EJ; McCulloch, TM; Victoria, L | 1 |
| Gardner, RV; Shetty, AK; Warrier, RP; Yu, LC | 1 |
| Bernstein, ML; Dubowy, RL; Fahey, RC; Newton, GL; Souid, AK | 1 |
| Boddy, AV; Brunner, J; Cerny, T; Honegger, P; Küpfer, A; Leyvraz, S; Schaad, R; Schmitz, SF; Sessa, C; von Briel, T | 1 |
| Andersson, LC; Blomqvist, CP; Böhling, TO; Huuhtanen, RL; Tribukait, B; Virolainen, MJ; Wiklund, TA | 1 |
| Albistur, JJ; Barnadas, A; Constenla, M; Estévez, LG; Frau, A; Lizón, J; Lobo, F; Martínez, P; Méndez, M; Provencio, M; Sánchez, MJ | 1 |
| Aziz, Z; Qazi, S; Rehman, A | 1 |
| Palangié, T; Pierga, JY; Pouillart, P | 1 |
| Conrad, EU; Felgenhauer, J; Hawkins, D; Lindsley, K; Miser, JS; Pendergrass, T | 1 |
| Blohmer, JU; Elling, D; Fleige, B; Grineisen, Y; Kissner, L; Lichtenegger, W; Paepke, S | 1 |
| Cabanillas, F; Hagemeister, FB; McLaughlin, P; Preti, A; Rodriguez, J; Rodriguez, MA; Romaguera, JE; Sarris, AH; Younes, A | 1 |
| Altundağ, K; Baltali, E; Barişta, I; Celik, I; Firat, D; Güler, N; Güllü, I; Kars, A; Ozişik, Y; Tekuzman, G; Türker, A; Uner, A; Yalçin, S; Zengin, N | 1 |
| Gimonet, JF; Kleisbauer, JP; Lena, H; Paillotin, D; Pibarot, M; Robinet, G; Thiberville, L; Thomas, P; Vergnenègre, A; Vernejoux, JM | 1 |
| Shin, DM | 1 |
| Bolanowska-Higdon, W; Creaven, PJ; Meropol, NJ; Murphy, M; Pendyala, L; Perez, R; Schwartz, G; Zdanowicz, J | 1 |
| Aleman, A; Anderlini, P; Bast, RC; Bevers, M; Bodurka-Bevers, D; Boyer, J; Burke, T; Champlin, RE; Donato, ML; Freedman, R; Gajewski, JG; Gershenson, D; Giralt, S; Ippoliti, C; Korbling, M; Lauppe, J; Levenback, C; Molldrem, J; Ueno, N; Wharton, JT; Wolf, J | 1 |
| Belinson, JL; Kennedy, AW; Kushner, DM; Markman, M; Rybicki, LA; Webster, KD | 1 |
| Amato, S; Barbieri, M; Boughen, JM; Domínguez, ME; Focaccia, G; Grasso, S; Lacava, JA; Langhi, MJ; Leone, BA; Machiavelli, MR; Ortiz, EH; Pérez, JE; Rodríguez, R; Romero Acuña, J; Romero Acuña, LA; Romero, AO; Scenna, M; Suttora, G; Vallejo, CT | 1 |
| Burt, PA; Davies, R; Hodgetts, J; Lee, SM; Lomax, L; Pettengell, R; Simms, T; Stout, R; Thatcher, N; Woll, PJ | 1 |
| Balaguer-Martínez, JV; Castillo-Pallarés, FJ; Ferrer Albiach, C; Pallardó-Calatayud, J; Romero-de-Avila, C; Ruiz Hernández, G | 1 |
| Hamakawa, H; Otsuka, K; Sumida, T; Tanioka, H | 1 |
| Apice, G; Azzarelli, A; Barbieri, E; Bonetti, M; Buonadonna, A; Comandone, A; De Paoli, A; Frustaci, S; Gherlinzoni, F; Olmi, P; Picci, P; Pignatti, G; Serraino, D; Zmerly, H | 1 |
| Shin, KH; Takita, H | 1 |
| Bangalore, N; Bhargava, P; Hawkins, MJ | 1 |
| Mazeron, JJ; Noël, G | 1 |
| Homori, M; Katayama, K; Kikuchi, F; Mochizuki, K; Saito, I | 1 |
| Cabanillas, FF; Cox, JD; Ha, CS; Hess, MA; Rodriguez, MA; Tucker, SL; Wilder, RB | 1 |
| Aggarwal, AN; Behera, D; Gupta, D; Jindal, SK; Sharma, SC | 1 |
| Cernilová, I; Doubek, M; Klabusay, M; Korístek, Z; Mayer, J; Navrátil, M; Petráková, K; Vásová, I; Vodvárka, P; Vorlícek, J | 1 |
| Crooke, MJ; Delahunt, B; Lewis, ME; Pringle, KC; Wiltshire, EJ | 1 |
| Hosomi, Y; Shibuya, M | 1 |
| Stewart, SL | 1 |
| Burgut, R; Erkisi, M; Erkurt, E; Kocabas, A; Tunali, C; Zeren, H | 1 |
| Diakomanolis, E; Dimopoulos, MA; Gika, D; Kiamouris, C; Kouroussis, C; Michalas, S; Moulopoulos, LA; Papadimitriou, CA; Rodolakis, A; Vlahos, G | 1 |
| Gorchev, G; Ianev, N; Ivanova, R; Marinov, E; Tsvetkov, Ch; Veselinova, T | 1 |
| Arush, MW; Beck, D; Ben-Izhak, O; Postovsky, S | 1 |
| Crespo, C; García-López, JL; Garrido, P; González-Martín, A; Lastra, E; Moyano, A; Pedraza, M | 1 |
| Buckner, JC; Edmonson, JH; Foo, ML; Gunderson, LL; Haddock, MG; Mahoney, MR; Maples, WJ; O'Connor, MI; Petersen, IA; Pritchard, DJ; Rock, MG; Shives, TC; Sim, FH; Stafford, SL | 1 |
| Ardizzoni, A; Baldini, E; Boni, L; Cafferata, MA; Prochilo, T; Tibaldi, C | 1 |
| Clayman, G; Diaz, E; Feng, L; Francisco, M; Garden, A; Ginsberg, L; Glisson, BS; Hong, WK; Khuri, FR; Kies, MS; Lippman, SM; Myers, J; Papadimitrakopoulou, V; Shin, DM | 1 |
| Chen, H; Chen, J; Fu, RY; Gu, LJ; Pan, C; Tang, JY; Wang, YP; Wu, Y; Xue, H; Zhao, H | 1 |
| Douglas, J; Felgenhauer, J; Gooley, T; Hawkins, DS; Kreissman, S; Park, J; Pendergrass, TW; Rowley, SD; Sanders, JE; Thomson, B | 1 |
| Cohen, MH; Dagher, R; Griebel, DJ; Ibrahim, A; Martin, A; Pazdur, R; Scher, NS; Sokol, GH; Williams, GA | 1 |
| Emmanouilides, C; Grody, W; Lill, M; Rosen, P; Rosenfelt, F; Telatar, M; Territo, M | 1 |
| Hu, L; Huang, YH; Wen, XP | 1 |
| Al Awadi, S; Al Shemmari, S; Bajciova, V; Mottl, H; Nemec, J | 1 |
| Baker, J; Hand, S; Macbeth, FR; Smith, AP | 1 |
| Haddad, R; Posner, M | 1 |
| Bell, RS; O'Sullivan, B | 1 |
| Ancukiewicz, M; DeLaney, TF; Gebhardt, MC; Harmon, DC; Hornicek, FJ; Mankin, HJ; Miryousefi, F; Rosenberg, AL; Rosenthal, DI; Spiro, IJ; Suit, HD | 1 |
| Springate, JE; Taub, M; Zaki, EL | 1 |
| Kitchell, BE; Moore, AS | 1 |
| Antman, KH; Baker, LH; Balcerzak, SP; Bhoopalam, N; Chapman, RA; Middleman, EL; Rankin, C; Talbot, SM; Taub, RN | 1 |
| Briggs, T; Cannon, S; Cassoni, AM; Cobb, J; Driver, D; Hall-Craggs, M; Kilby, A; McTiernan, A; Michelagnoli, M; Pringle, J; Sandison, A; Strauss, SJ; Whelan, JS; Witt, J | 1 |
| GROSSE, W | 1 |
| SCHAULOW, I | 1 |
| Bevers, MW; Broaddus, R; Burke, TW; Jhingran, A; Levenback, CF; Ramondetta, LM; Schmandt, R; Wolf, JK | 1 |
| Bearz, A; Cartei, G; Clocchiatti, L; Mantero, J; Pastorelli, D; Pella, N; Sacco, C; Salmaso, F; Zustovich, F | 1 |
| Booker, BM; Creaven, P; Pendyala, L; Perez, R; Smith, PF | 1 |
| Belarmino-Filho, JN; Brito, GA; Cunha, FQ; Macedo, FY; Nery, EA; Ribeiro, RA; Vieira, MM | 1 |
| Baker, LH; Bernardy, H; Demetri, G; Junge, K; Keohan, ML; Mace, JR; Mueller, U; Niebch, G; Romeis, P; Thoma, A; Wagner, T | 1 |
| Davidson, KL; Devaney, MB; Dunlop, DJ; Johnson, PR; Mackie, MJ; Rogers, SY; Thomas, RV; Tighe, JE | 1 |
| Bahrs, H; Gruber, Y; Kempgens, B; Kisro, J; Wagner, T | 1 |
| Inoue, H; Kunisada, T; Morimoto, Y; Ohata, N; Ozaki, T; Tanaka, M | 1 |
| Fisher, D; Howard, O; Lacasce, A; Lib, S; Neuberg, D; Shipp, M; Weng, A | 1 |
| Bush, DA; Epelman, S; Goren, MP | 1 |
| Fisher, C; Hemmings, C | 1 |
| Alper, F; Eroğlu, A; Gündoğdu, C; Karaoğlanoğlu, N; Kürkçüoğlu, IC | 1 |
| Assimakopoulos, SF; Kortsaris, A; Scopa, CD; Simopoulos, C; Tentes, I; Ypsilantis, P | 1 |
| Avramis, V; Douglas, JG; Felgenhauer, J; Geyer, JR; Hawkins, DS; Holcenberg, J; Loken, MR; Meshinchi, S; Park, JR; Thomson, B | 1 |
| Goto, T; Hozumi, T; Kobayashi, H; Kondo, T; Kosaku, H | 1 |
| Brennan, MF; Demetri, GD; Grobmyer, SR; Maki, RG; Mazumdar, M; Riedel, E; Singer, S | 1 |
| Baldinger, C; Fridrik, MA; Greil, R; Hausmaninger, H; Klocker, J; Krieger, O; Linkesch, W; Oberaigner, W; Pont, J | 1 |
| Altinbas, M; Coskun, HS; Ekici, E; Er, O; Eser, B; Gulmez, I; Kaplan, B; Ozesmi, M; Ozkan, M | 1 |
| Coleman, M; Olver, I; Yap, YS | 1 |
| Akbulut, H; Buyukcelik, A; Demirkazik, A; Icli, F; Pamir, A; Utkan, G; Yalcin, B | 1 |
| Devidas, M; Gebhardt, M; Grier, HE; Jenkins, J; Marcus, R; Pappo, AS; Pratt, C; Rao, B; Thomas, P | 1 |
| Caruso, D; Keefe, D; Myers, M; Olver, I | 1 |
| Briceño, H; Cervera, JM; Esquerdo, G; Llorca, C | 1 |
| Ceylaner, B; Dervişoğlu, S; Dinçbaş, FO; Hiz, M; Koca, S; Mandel, NM; Oksüz, DC; Seçmezacar, H; Uzel, B | 1 |
| Burger, CW; Ewing, P; Seynaeve, C; Snijders-Keilholz, A | 1 |
| Bazari, H; Forman, JP; Humphreys, BD; Magee, CC; Seifter, J; Zandi-Nejad, K | 1 |
| Piura, B; Rabinovich, A | 1 |
| Ball, HG; Chen, AH; Li, C; Quesenberry, CD; Zweizig, SL | 1 |
| Anderson, ME; Gebhardt, MC; Hornicek, FJ; Mankin, HJ; Raskin, KA | 1 |
| Pisters, PW | 1 |
| Blum, RH; DeLaney, TF; Eisenberg, B; Ettinger, DS; Harmon, DC; Harris, J; Kraybill, WG; Letson, GD; Lucas, DR; Spiro, IJ | 1 |
| Baur, M; Dittrich, C; Fazeny-Doerner, B; Hudec, M; Salzer, H; Sevelda, P | 1 |
| Chaffin, K; Khanna, C; Kristal, O; Page, RL; Rassnick, KM; Rodriguez, CO; Rosenberg, MP | 1 |
| Clarke, PM; Sandison, A; Tysome, JR | 1 |
| Allard, D; Berger, C; Cottalorda, J; Ferigo, N; Fessy, M; Gentil-Perret, A; Stéphan, JL | 1 |
| Kageyama, Y; Kihara, K; Kobayashi, T; Kubo, Y; Yokoyama, M | 1 |
| Bisogno, G; Carli, M; Casanova, M; Ferrari, A; Meazza, C; Zanetti, I | 1 |
| de Castro Brito, GA; Ferreira, FV; Lima, MV; Macedo, FY; Ribeiro, RA | 1 |
| Beck-Schimmer, B; Biber, J; Hernando, N; Murer, H; Patzer, L; Ziegler, U | 1 |
| Albert, M; Holloway, CL; Muto, M; Russell, AH; Viswanathan, AN | 1 |
| Springate, J; Taub, M | 1 |
| Crişan, D; Domşa, I; Olinici, CD | 1 |
| Hasegawa, T; Ichihara, K; Itoh, N; Masumori, N; Taguchi, K; Takagi, Y; Takahashi, A; Takahashi, S; Tsukamoto, T | 1 |
| Korkmaz, A; Oter, S; Topal, T | 1 |
| Crotzer, DR; Gano, JB; Gershenson, DM; Levenback, C; Wolf, JK | 1 |
| Arceci, RJ; Chen, AR; Colombani, P; Higman, MA; Schwartz, CL; Wharam, M; Williams, KM | 1 |
| Burke, MJ; Duerst, RE; Jacobsohn, DA; Kletzel, M; Walterhouse, DO | 1 |
| Bakshi, A; Gujral, S; Gupta, S; Nair, R; Parikh, P; Prabhash, K; Sengar, M | 1 |
| Almeida, PR; Baltazar, F; Brito, GA; Ferreira, FV; Macedo, FY; Ribeiro, RA; Schmitt, FC; Távora, F | 1 |
| Brady, MF; Cohn, DE; Futoran, RJ; Ioffe, OB; Lee, YC; Mannel, RS; Rocereto, T; Wolfson, AH | 1 |
| Guan, ZZ; Huang, HQ; Jiang, WQ; Li, FH; Lin, TY; Luo, HY; Qiu, MZ; Sun, XF; Wang, F; Wang, SS; Xu, F; Xu, GC; Xu, RH | 1 |
| Chandra, P; Madan, P; Schmidt, RM; Topkara, VK | 1 |
| Baba, H; Imamura, Y; Inukai, T; Kobayashi, S; Nakajima, H; Noriki, S; Orwotho, N; Uchida, K; Yayama, T | 1 |
| Chesnutt, DA; Cummings, TJ; Heimann, A; Morris, CL; Mukundan, S | 1 |
| Chabaud, S; Court-Fortune, I; Falandry, C; Fournel, C; Freyer, G; Girard, P; Ribba, B; Souquet, PJ; Tod, M; Tranchand, B; Trillet-Lenoir, V; You, B | 1 |
| Carmichael, M; Collen, J; Wroblewski, T | 1 |
| Choti, MA; Pesce, CE; Thornton, K | 1 |
| Baba, S; Hosokawa, S; Mineta, H; Suzuki, K; Takebayashi, S | 1 |
| Arpaci, F; Ataergin, S; Beyzadeoglu, M; Komurcu, S; Oysul, K; Ozet, A; Ozturk, M; Solchaga, L; Surenkok, S; Turan, M | 1 |
| Gutweiler, JR; Kim, HB; Kozakewich, HP; Marcus, KJ; Shamberger, RC; Weldon, CB; Yu, DC | 1 |
| Bertani, A; Di Benedetto, G; Forlini, W; Grassetti, L; Scalise, A; Sperti, V | 1 |
| Funayama, Y; Ohara, G; Satoh, H; Uchida, K | 1 |
| Aravantinos, G; Bamias, A; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Mountzios, G; Papadimitriou, CA; Vourli, G | 1 |
| Alexandre, J; Anract, P; Billemont, B; Camps, S; Coriat, R; Goldwasser, F; Larousserie, F; Leconte, M; Mir, O; Ropert, S | 1 |
| Al-Kadhimi, Z; Chow, WA; Frankel, P; Kapoor, N; Lashkari, A; Leong, L; Molina, A; Phan, V; Somlo, G; Twardowski, P; Valdes, F | 1 |
| Domm, J; Eckrich, MJ; Frangoul, H; Ho, R; Whitlock, JA | 1 |
| Akbulut, H; Buyukcelik, A; Demirkazik, A; Dincol, D; Dogan, M; Icli, F; Onur, H; Samur, M; Senler, FC | 1 |
| Dyck, J; Huizing, MT; Rasschaert, M; Schrijvers, D; Specenier, P; Van den Brande, J; Vermorken, JB | 1 |
| Fujimura, T; Homma, Y; Kume, H; Sugihara, T | 1 |
| Anderson, P | 1 |
| Brito, GA; Jucá, DM; Lima, RC; Macedo, FY; Magalhães, PJ; Mourão, LT; Neto, Jde S; Palheta, RC; Ribeiro, RA; Santos, AA; Souza, MH | 1 |
| El-Baz, M; Ghali, AM; Ghoneim, MA; Sarhan, MM; Sarhan, OM | 1 |
| Bang, SM; Chung, JH; Kim, JH; Kim, YJ; Lee, JS; Lee, KW | 1 |
| Castellano, A; De Ioris, MA; De Pasquale, MD; De Vito, R; Donfrancesco, A; Garganese, MC; Ilari, I; Inserra, A; Jenkner, A; Locatelli, F; Natali, G; Ravà, L | 1 |
| Ferreti Bonan, PR; Martelli-Júnior, H; Miranda Soares, PB; Pereira DE Souza, W; Quirino Filho, S | 1 |
| Aoyagi, Y; Kato, H; Minobe, S; Okamoto, K; Suzuki, Y; Todo, Y; Umazume, T | 1 |
| Pazos Arias, B; Peteiro Cancelo, A; Romero Reinoso, C; Samprón Rodríguez, M; Vello Román, A | 1 |
| Brito, GA; Cunha, FQ; Freitas, HC; Lima, RC; Macedo, FY; Mourão, LT; Oriá, RB; Ribeiro, RA; Vale, ML; Wong, DV | 1 |
| Camus, M; Guillet, G; Hainaut-Wierzbicka, E; Levillain, P; Lopez, L; Saulnier, JP | 1 |
| Chen, N; Hanly, L; Koren, G; Rieder, M; Yeger, H | 1 |
| Bay, JO; Blay, JY; Bonichon, F; Bui-Nguyen, B; Chevreau, C; Coindre, JM; Cupissol, D; Italiano, A; Jimenez, M; Lotz, JP; Mathoulin-Pélissier, S; Penel, N; Ray-Coquard, I; Thyss, A | 1 |
| Anderson, JR; Dasgupta, R; Gupta, AA; Hawkins, DS; Indelicato, DJ; Pappo, AS; Spunt, SL | 1 |
| Dawson, JL; Field, TL; Fields, KK; Goldstein, SC; Kim, J; Lush, RM; Maddox, BL; Neuger, AM; Partyka, JS; Perkins, JB; Simonelli, CE; Sullivan, DM | 1 |
| Akiyama, T; Goto, T; Hirata, M; Imanishi, J; Kawano, H; Kobayashi, H; Ogura, K; Okuma, T; Shinoda, Y; Tsuda, Y; Yamamoto, A | 1 |
| Chen, YL; Choy, E; DeLaney, TF; Harmon, DC; Hornicek, FJ; Kobayashi, W; Mullen, JT; Rosenberg, AE; Spiro, IJ; Wang, JJ | 1 |
| Avci, Z; Gursel, O; Kurekci, E; Malbora, B; Olgac, A; Ozbek, N | 1 |
| Chen, Y; Shi, Y; Wang, C; Yang, Y | 1 |
| Adde, M; Adeodou, O; Aken'Ova, Y; Brown, BJ; Durosinmi, M; Githang'a, J; Hurwitz, N; Kaijage, J; Leoncini, L; Magrath, I; Naresh, K; Ngoma, T; Rajab, J; Raphael, M; Rohatiner, A; Scanlan, P; Venzon, D | 1 |
| Chen, YL; Choy, E; DeLaney, TF; Harmon, DC; Hornicek, FJ; Look Hong, NJ; Mullen, JT; Nielsen, GP; Szymonifka, J; Yeap, BY; Yoon, SS | 1 |
| Aubert, M; Coudurier, M; Deroux, A; Destors, M; Girard, N; Lantuejoul, S; Moro-Sibilot, D | 1 |
| Fujikawa, Y; Ichikawa, N; Kirihara, T; Kobayashi, H; Nakamura, S; Sato, K; Shimizu, I; Sumi, M; Takeda, W; Uehara, T; Ueki, T; Ueno, M; Watanabe, M | 1 |
| Yang, Y; Zhao, J | 1 |
| Anderson, PM; Culotta, KS; Kawedia, JD; Kramer, MA; McIntyre, CM; Myers, AL; Zhang, Y | 1 |
| Abate, ME; Balladelli, A; Cesari, M; Fagioli, F; Ferrari, S; Luksch, R; Marchesi, E; Paioli, A; Palmerini, E; Pratelli, L; Tamburini, A | 1 |
| Dervisoglu, S; Dincbas, FO; Hiz, M; Kantarci, F; Koca, S; Mandel, NM; Oksuz, DC; Turna, H; Yetmen, O | 1 |
| Bai, L; Greenwood, M; Kerridge, I; Ma, CK; Reid, C; Ward, C; Wong, K; Xia, W | 1 |
| Huang, SC; Wu, PC; Yue, CT | 1 |
| Barton, S; Nabhani-Gebara, S; Peron, JM; Salman, D; Swinden, J | 1 |
| Grosman, G; Iturbe, J; Leone, BA; Leone, J; Leone, JP; Pérez, JE; Vallejo, CT; Verdera, PP; Zwenger, AO | 1 |
| Aslam, S; Dandamudi, RK; El-Modir, A; Fernando, I; Walji, N | 1 |
| DiPersio, JF; Fletcher, TR; Hsu, YM; Link, DC; Schmidt, AP; Stock, W; Trinkaus, KM; Uy, GL; Westervelt, P | 1 |
| Abu-Khalaf, MM; Azodi, M; Hatzis, C; Higgins, S; Lin, K; Ratner, E; Raza, MA; Rutherford, TJ; Santin, AD; Schwartz, PE; Silasi, DA; Wang, H | 1 |
| Kumamoto, T; Makino, Y; Ogawa, C; Saito, Y; Tamai, I; Terakado, H | 1 |
| Hsieh, MH; Matz, EL | 1 |
| Al Sa'ey, H; Al Shawabkeh, MA; Al Sulaiti, M; Ganesan, S | 1 |
| Fujita, H; Kadono, T; Kimura, T; Masui, Y; Miyagaki, T; Miyagawa, T; Saigusa, R; Sato, S; Yamada, D; Yoshizaki, A | 1 |
| Belau, A; Eichbaum, M; Grokopf, V; Koensgen, D; Köhler, G; Ledwon, P; Lichtenegger, W; Mustea, A; Sehouli, J; Stope, MB; Weiss, M; Zygmunt, M | 1 |
| Babre, F; Brouste, V; Henriques de Figueiredo, B; Italiano, A; Kind, M; Le Loarer, F; Michot, A; Rigal, L; Sargos, P; Stoeckle, E; Toulmonde, M | 1 |
| Inatsu, H; Kitamura, K; Nakashima, K | 1 |
| Abrams, RA; Batus, M; Chowdhary, M; Gitelis, S; Jeans, EB; Miller, L; Sen, N; Wang, D | 1 |
| Andersson, LC; Böhling, T; Fagerstedt, KW; Kytölä, S; Salonen, T; Zhao, F | 1 |
| Alencar, NMN; Almeida, PRC; Alves, APNN; Araújo, LCNC; Bingana, RD; Cunha, FQ; Dornelas-Filho, AF; Lima-Júnior, RCP; Melo, AT; Nobre, LMS; Nour, ML; Pereira, VBM; Pinto, FMM; Silva, CMS; Silva, PGB; Silva, RO; Souza, MHLP; Wanderley, CWS; Wong, DVT | 1 |
| Ahn, JS; Choi, S; Choi, YL; Han, J; Jung, HA; Kim, Y; Lee, J; Lee, SH; Park, K; Sun, JM | 1 |
| Li, D; Liu, Y; Qiao, L; Sun, M; Wang, L; Xu, S | 1 |
| DeBlanche, L; Kondapalli, A; Oo, Y; Redd, L | 1 |
| Fujita, T; Fukushima, N; Kitayama, J; Koike, R; Lefor, AK; Miyazaki, C; Mizunuma, H; Nishida, S; Ogihara, K; Sakuragi, M; Sasaki, Y; Sata, N; Shiba, S; Shiozawa, M | 1 |
| Copeland, VC; Cranmer, LD; Hammer, KJ; Loggers, ET; Pollack, SM; Wagner, MJ | 1 |
| Cui, Y; Pan, Y; Shi, X | 1 |
| Anderson, PM; Pierson, CE; Plutt, AA; Stanton, MP; Zahler, S; Zembillas, AS | 1 |
| Boskabadi, J; Salehifar, E; Yousefi-Mazhin, E | 1 |
| Ballatore, Z; Berardi, R; Catania, C; Conforti, F; Corti, C; Curigliano, G; De Pas, TM; Di Venosa, B; Maiettini, D; Pala, L; Salvini, P; Varano, G; Vivanet, G | 1 |
| Clementino, M; da Silva, JA; de Freitas, TM; Ferreira, FCS; Havt, A; Lima, AAM; Lima, MA; Martins, DS; Mota, MRL; Queiroga, ML; Ribeiro, SA; Rodrigues, FAP; Silva, DO; Veras, HN | 1 |
46 review(s) available for ifosfamide and mesna
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Ifosfamide is an active drug for chemotherapy of metastatic cystosarcoma phyllodes.
Topics: Adult; Breast Neoplasms; Female; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Metastasis; Phyllodes Tumor | 1992 |
Neoadjuvant therapy for cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Female; Humans; Ifosfamide; Leukopenia; Mesna; Middle Aged; Remission Induction; Thrombocytopenia; Uterine Cervical Neoplasms | 1992 |
Oral mesna: a review.
Topics: Administration, Oral; Animals; Humans; Ifosfamide; Mesna | 1992 |
Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.
Topics: Drug Evaluation; Drug Therapy, Combination; Female; Humans; Ifosfamide; Male; Mesna; Neoplasms | 1991 |
Dosing and side-effects of ifosfamide plus mesna.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Humans; Ifosfamide; Infusions, Intravenous; Mesna | 1991 |
Chemoprotectants for cancer chemotherapy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Cisplatin; Cyclophosphamide; Fluorouracil; Humans; Ifosfamide; Leucovorin; Mesna; Methotrexate; Neoplasms; Razoxane; Sulfhydryl Compounds; Uridine | 1991 |
Ifosfamide and mesna.
Topics: Animals; Humans; Ifosfamide; Mercaptoethanol; Mesna; Neoplasms | 1990 |
[New treatments for urogenital toxicity of anti-neoplastic chemotherapy].
Topics: Antidotes; Antineoplastic Agents; Cisplatin; Humans; Ifosfamide; Kidney Diseases; Mesna; Thiosulfates | 1990 |
Mitomycin, ifosfamide, and mesna in the treatment of lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance; Humans; Ifosfamide; Lung Neoplasms; Mercaptoethanol; Mesna; Mitomycins | 1990 |
Oxazaphosphorine cytostatics: past-present-future. Seventh Cain Memorial Award lecture.
Topics: Cyclophosphamide; Humans; Ifosfamide; Mesna; Organ Specificity | 1989 |
Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Doxorubicin; Humans; Ifosfamide; Mesna; Randomized Controlled Trials as Topic; Salvage Therapy; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome; Vincristine | 1995 |
Strategies to prevent nephrotoxicity of anticancer drugs.
Topics: Adult; Antineoplastic Agents; Cell Line; Chelating Agents; Child; Child, Preschool; Cisplatin; Humans; Ifosfamide; Kidney; Kidney Diseases; Kidney Tubules; Mesna; Neoplasms; Prognosis; Risk Factors; Thiosulfates | 1995 |
Osteosarcoma studies at St. Jude Children's Research Hospital from 1968 through 1990.
Topics: Amputation, Surgical; Bone Neoplasms; Chemotherapy, Adjuvant; Child; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Humans; Ifosfamide; Leucovorin; Lung Neoplasms; Mesna; Osteosarcoma; Survival Analysis; Tennessee; Treatment Outcome; Vincristine | 1993 |
An opinion supporting the role of high-dose methotrexate in the treatment of osteosarcoma.
Topics: Acidosis, Renal Tubular; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Doxorubicin; Humans; Ifosfamide; Leucovorin; Mesna; Methotrexate; Osteosarcoma; Postoperative Care; Preoperative Care; Radionuclide Imaging; Retrospective Studies; Salvage Therapy; Thallium Radioisotopes; Treatment Outcome | 1993 |
Ifosfamide and mesna in epithelial ovarian carcinoma.
Topics: Carcinoma; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Ifosfamide; Mesna; Ovarian Neoplasms; Urologic Diseases | 1993 |
Ifosfamide. Patient care management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Ifosfamide; Mesna; Patient Care Planning | 1993 |
Ifosfamide-induced hyperpigmentation.
Topics: Child, Preschool; Etoposide; Humans; Ifosfamide; Kidney Neoplasms; Lung Neoplasms; Male; Mesna; Pigmentation Disorders; Wilms Tumor | 1993 |
Ifosfamide, mesna, and nephrotoxicity in children.
Topics: Child; Humans; Ifosfamide; Kidney Diseases; Mesna; Risk Factors | 1993 |
Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience.
Topics: Acetylcysteine; Bone Neoplasms; Fluid Therapy; Humans; Ifosfamide; Mesna; Randomized Controlled Trials as Topic; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome; Urinary Bladder Diseases | 1993 |
Ifosfamide in the treatment of soft tissue sarcomas.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Fluid Therapy; Humans; Ifosfamide; Mesna; Pilot Projects; Randomized Controlled Trials as Topic; Sarcoma; Urinary Tract | 1996 |
Ifosfamide in non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Expectorants; Humans; Ifosfamide; Liver; Lung Neoplasms; Mesna; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate | 1996 |
Ongoing clinical studies of ifosfamide for pediatric cancer in the United States.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials as Topic; Humans; Ifosfamide; Leukemia; Mesna; Multicenter Studies as Topic; Neoplasms; Sarcoma; United States | 1996 |
Oral administration of mesna with ifosfamide.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents, Alkylating; Cystitis; Drug Administration Schedule; Europe; Hematuria; Hemorrhage; Humans; Ifosfamide; Injections, Intravenous; Mesna; Tablets; United States | 1996 |
[Locally developed sarcoma of the thoracic wall].
Topics: Antineoplastic Combined Chemotherapy Protocols; Back; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Doxorubicin; Humans; Ifosfamide; Magnetic Resonance Imaging; Male; Mesna; Middle Aged; Neoplasm Invasiveness; Prognosis; Radiotherapy Dosage; Sarcoma; Soft Tissue Neoplasms; Thoracic Neoplasms | 1996 |
Factors that influence prognosis of intermediate-grade lymphomas at relapse.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Cisplatin; Cytarabine; Etoposide; Humans; Ifosfamide; L-Lactate Dehydrogenase; Lymphoma, Non-Hodgkin; Mesna; Methylprednisolone; Middle Aged; Mitoxantrone; Outcome Assessment, Health Care; Prognosis | 1996 |
Neoadjuvant chemotherapy followed by radiotherapy should not be a standard approach for locally advanced cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Female; Humans; Ifosfamide; Mesna; Mitomycins; Neoplasm Staging; Randomized Controlled Trials as Topic; Uterine Cervical Neoplasms; Vincristine | 1998 |
Use of mesna to prevent ifosfamide-induced urotoxicity.
Topics: Antineoplastic Agents, Alkylating; Drug Administration Schedule; Humans; Ifosfamide; Kidney; Mesna; Renal Insufficiency | 1998 |
Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Esthesioneuroblastoma, Olfactory; Etoposide; Fatal Outcome; Female; Humans; Ifosfamide; Lymphatic Metastasis; Male; Mesna; Methotrexate; Middle Aged; Mitomycin; Nasal Cavity; Nose Neoplasms; Paranasal Sinus Neoplasms; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome; Vincristine | 1998 |
The role of ifosfamide in paediatric cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Child; Humans; Ifosfamide; Mesna; Neoplasms; Treatment Outcome | 1998 |
Malignant triton tumor of the head and neck: A case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Child; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Fatal Outcome; Female; Head and Neck Neoplasms; Humans; Ifosfamide; Lung Neoplasms; Magnetic Resonance Imaging; Mesna; Neoplasm Recurrence, Local; Neurilemmoma; Radiotherapy Dosage; Vincristine | 1999 |
Paclitaxel (Taxol)/ifosfamide-based chemotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Head and Neck Neoplasms; Humans; Ifosfamide; Mesna; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 2000 |
Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Dacarbazine; Doxorubicin; Humans; Ifosfamide; Kidney Neoplasms; Male; Mesna; Middle Aged; Sarcoma; Tomography, X-Ray Computed | 2001 |
[Combination chemotherapy with VP-16 in the treatment of lung cancer and malignant lymphoma].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase II as Topic; Cytarabine; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Lymphoma; Mesna; Methylprednisolone; Mitoxantrone | 2001 |
Secondary thyroid carcinoma after treatment for clear cell carcinoma of the uterus: case report and review of the literature.
Topics: Adenocarcinoma, Clear Cell; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Lymphatic Metastasis; Mesna; Neoplasms, Second Primary; Radiotherapy, Adjuvant; Thyroid Neoplasms; Thyroidectomy; Uterine Neoplasms; Vincristine | 2001 |
Gemcitabine, ifosfamide and Navelbine (GIN): a platinum-free combination in advanced non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Mesna; Middle Aged; Protective Agents; Vinblastine; Vinorelbine | 2002 |
New chemotherapy agents in veterinary medicine.
Topics: Animals; Antineoplastic Agents; Cat Diseases; Cats; Deoxycytidine; Dog Diseases; Dogs; Gemcitabine; Ifosfamide; Lomustine; Mesna; Neoplasms; Streptozocin; Veterinary Drugs | 2003 |
[Soft tissue sarcoma: postoperative chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Dactinomycin; Doxorubicin; Drug Administration Schedule; Humans; Ifosfamide; Melphalan; Mesna; Methotrexate; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Soft Tissue Neoplasms; Vincristine | 2004 |
Primitive neuroectodermal tumor of the cervix uteri: a case report -- changing concepts in therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dactinomycin; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Mesna; Neoadjuvant Therapy; Neuroectodermal Tumors, Primitive, Peripheral; Uterine Cervical Neoplasms; Vincristine | 2005 |
Myxoid liposarcoma metastatic to the thyroid gland: a case report and literature review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Doxorubicin; Humans; Ifosfamide; Liposarcoma, Myxoid; Lung Neoplasms; Male; Mesna; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Thigh; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed | 2006 |
Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation.
Topics: Acrolein; Antineoplastic Agents; Cell Death; Cyclophosphamide; Cystitis; Cytokines; DNA Damage; Enzyme Activation; Hemorrhage; Humans; Ifosfamide; Lipid Peroxidation; Mesna; Nitrogen; Oxygen; Poly(ADP-ribose) Polymerases; Reactive Oxygen Species; Transcription Factors | 2007 |
Multidisciplinary management of metastatic sarcoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Doxorubicin; Humans; Ifosfamide; Lung Neoplasms; Mesna; Sarcoma; Treatment Outcome | 2008 |
Bilateral Wilms' tumors: single-center experience with 22 cases and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Child; Child, Preschool; Combined Modality Therapy; Dactinomycin; Doxorubicin; Egypt; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Infant; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Mesna; Neoadjuvant Therapy; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Nephrectomy; Retrospective Studies; Treatment Outcome; Vincristine; Wilms Tumor | 2010 |
Complete response after MAID treatment for advanced primary ovarian angiosarcoma: case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Female; Hemangiosarcoma; Humans; Ifosfamide; Mesna; Middle Aged; Ovarian Neoplasms | 2014 |
Evaluation of the stability profile of anticancer drugs: A review of Ifosfamide and Mesna regimen for the treatment of metastatic soft tissue sarcoma.
Topics: Antineoplastic Agents; Drug Stability; Humans; Ifosfamide; Mesna; Sarcoma | 2016 |
Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-induced Hemorrhagic Cystitis.
Topics: Antineoplastic Agents, Alkylating; Cyclophosphamide; Cystitis; Hemorrhage; Humans; Ifosfamide; Mesna; Protective Agents | 2017 |
186 trial(s) available for ifosfamide and mesna
| Article | Year |
|---|---|
Modified cisplatin, etoposide (or vinblastine) and ifosfamide salvage therapy for male germ-cell tumors. Long-term results.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Male; Mediastinal Neoplasms; Mesna; Middle Aged; Neoplasms, Germ Cell and Embryonal; Retroperitoneal Neoplasms; Testicular Neoplasms; Vinblastine | 1992 |
Second-line carboplatin-based chemotherapy for small cell lung cancer: the Groningen experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Pilot Projects; Remission Induction; Survival Rate; Vincristine | 1992 |
Neoadjuvant therapy for cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Female; Humans; Ifosfamide; Leukopenia; Mesna; Middle Aged; Remission Induction; Thrombocytopenia; Uterine Cervical Neoplasms | 1992 |
A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfamide; Male; Mesna; Mesothelioma; Middle Aged; Peritoneal Neoplasms; Pleural Neoplasms; Remission Induction; Survival Analysis; Testicular Neoplasms | 1992 |
An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma.
Topics: Drug Administration Schedule; Female; Humans; Ifosfamide; Infusions, Intravenous; Kidney Diseases; Male; Mesna; Mesothelioma; Middle Aged; Peritoneal Neoplasms; Pleural Neoplasms; Proportional Hazards Models; Survival Analysis | 1992 |
Ifosfamide, vincristine, doxorubicin and dacarbazine in adult patients with advanced soft-tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Female; Humans; Ifosfamide; Male; Mesna; Middle Aged; Sarcoma; Soft Tissue Neoplasms; Vincristine | 1992 |
Phase II trial of ifosfamide/mesna and mitoxantrone in previously treated patients with non-Hodgkin's lymphoma: cancer and leukemia group B study 8753.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Mitoxantrone; Remission Induction; Survival Rate | 1992 |
Feasibility and efficacy of arginine 2-mercaptoethanesulfonate (ARGIMESNA) in the prevention of hemorragic cystitis from ifosfamide (IFO).
Topics: Adolescent; Adult; Aged; Cystitis; Female; Hemorrhage; Humans; Ifosfamide; Male; Mesna; Middle Aged | 1992 |
Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease.
Topics: Acute Kidney Injury; Adult; Aged; Carcinoma; Drug Evaluation; Drug Resistance; Female; Humans; Ifosfamide; Mesna; Middle Aged; Ovarian Neoplasms; Platinum | 1992 |
Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Drug Administration Schedule; Drug Evaluation; Female; Humans; Ifosfamide; Infusions, Intravenous; Male; Mesna; Middle Aged; Pancreatic Neoplasms; Remission Induction | 1991 |
A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Combined Modality Therapy; Creatinine; Drug Administration Schedule; Drug Evaluation; Female; Hematologic Diseases; Humans; Ifosfamide; Kidney Diseases; Male; Mesna; Middle Aged; Neoplasms; Neoplasms, Germ Cell and Embryonal; Nervous System Diseases; Sarcoma; Survival Rate | 1991 |
Ifosfamide continuous infusion without mesna. A phase I trial of a 14-day cycle.
Topics: Adult; Aged; Drug Administration Schedule; Drug Evaluation; Female; Hematuria; Humans; Ifosfamide; Infusions, Intravenous; Leukopenia; Male; Mesna; Middle Aged; Nausea | 1991 |
Ifosfamide and mesna for the treatment of advanced squamous cell head and neck cancer. A GETLAC study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Ifosfamide; Male; Mesna; Middle Aged | 1991 |
Phase II trial of ifosfamide in recurrent and metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Drug Evaluation; Head and Neck Neoplasms; Humans; Ifosfamide; Leukocyte Count; Male; Mesna; Middle Aged; Neoplasm Recurrence, Local; Platelet Count; Survival Rate | 1991 |
Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders.
Topics: Adult; Aged; Double-Blind Method; Female; Hematuria; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Pain; Urination Disorders; Urologic Diseases | 1991 |
Dana-Farber Cancer Institute studies in advanced sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Central Nervous System Diseases; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Doxorubicin; Drug Administration Schedule; Female; Heart Diseases; Humans; Ifosfamide; Lung Diseases; Male; Mesna; Middle Aged; Randomized Controlled Trials as Topic; Sarcoma; Survival Analysis; Urologic Diseases | 1990 |
Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Child; Child, Preschool; Cystitis; Drug Administration Schedule; Drug Evaluation; Hematologic Diseases; Humans; Ifosfamide; Kidney Diseases; Mesna; Middle Aged; Pulmonary Fibrosis; Sarcoma | 1990 |
Epidoxorubicin plus ifosfamide in advanced and/or metastatic soft-tissue sarcomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation; Epirubicin; Humans; Ifosfamide; Mesna; Methylprednisolone; Metoclopramide; Middle Aged; Soft Tissue Neoplasms; Time Factors | 1990 |
[The use of holoxan (iphosphamide) in malignant tumors].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Ifosfamide; Infusions, Intravenous; Mesna; Middle Aged; Neoplasms; Remission Induction | 1990 |
Ifosfamide in soft tissue sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Dactinomycin; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Male; Mesna; Sarcoma; Soft Tissue Neoplasms | 1990 |
Phase II trial of ifosfamide in the treatment of metastatic hormone-refractory patients with prostatic cancer.
Topics: Aged; Drug Administration Schedule; Humans; Ifosfamide; Male; Mesna; Middle Aged; Prostatic Neoplasms; Survival Analysis | 1990 |
Gynecologic Oncology Group experience with ifosfamide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Drug Evaluation; Female; Genital Neoplasms, Female; Hematologic Diseases; Humans; Ifosfamide; Leiomyosarcoma; Mesna; Middle Aged; Multicenter Studies as Topic; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Remission Induction; Uterine Cervical Neoplasms; Uterine Neoplasms | 1990 |
[Multicenter prospective risk-adapted study on the therapy of non-Hodgkin's lymphomas of high malignancy. Use of COP-BLAM/IMVP-16 and randomized adjuvant radiotherapy--study concept and preliminary results].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Mesna; Methotrexate; Prednisone; Procarbazine; Vincristine | 1988 |
[Risk-adapted therapy of highly malignant non-Hodgkin's lymphomas with COP-BLAM/IMVP-16: a prospective multicenter study].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Mesna; Methotrexate; Middle Aged; Prednisone; Procarbazine; Prospective Studies; Risk Factors; Vincristine | 1989 |
Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Clinical Trials as Topic; Female; Hematuria; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; Middle Aged; Sarcoma; Soft Tissue Neoplasms | 1989 |
Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Female; Humans; Ifosfamide; Male; Mesna; Middle Aged; Remission Induction; Sarcoma; Soft Tissue Neoplasms; Spinal Cord Neoplasms | 1989 |
Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study.
Topics: Carcinoma; Drug Evaluation; Female; Humans; Ifosfamide; Leukocyte Count; Mercaptoethanol; Mesna; Multicenter Studies as Topic; Ovarian Neoplasms; Platelet Count | 1989 |
Experience with 24-h infusions of ifosfamide/mesna in small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Drug Evaluation; Humans; Ifosfamide; Infusions, Intravenous; Lung Neoplasms; Mercaptoethanol; Mesna | 1986 |
Doxorubicin, ifosfamide, and dacarbazine (AID) with mesna uroprotection for advanced untreated sarcoma: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Doxorubicin; Drug Evaluation; Female; Humans; Ifosfamide; Male; Mesna; Middle Aged; Sarcoma | 1986 |
The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial.
Topics: Adult; Aged; Clinical Trials as Topic; Cystitis; Female; Hemorrhage; Humans; Ifosfamide; Lung Neoplasms; Male; Mercaptoethanol; Mesna; Middle Aged; Random Allocation | 1986 |
Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas.
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Evaluation; Female; Humans; Ifosfamide; Infections; Leukopenia; Male; Mesna; Middle Aged; Random Allocation; Sarcoma; Soft Tissue Neoplasms | 1986 |
Phase II trial of ifosfamide and mesna in advanced colorectal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; Drug Evaluation; Female; Humans; Ifosfamide; Male; Mesna; Middle Aged; Rectal Neoplasms | 1987 |
Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas.
Topics: Adult; Aged; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; Middle Aged; Pancreatic Neoplasms | 1988 |
Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma.
Topics: Acrolein; Carcinoma, Bronchogenic; Clinical Trials as Topic; Cyclophosphamide; Female; Hematuria; Humans; Ifosfamide; Kinetics; Lung Neoplasms; Male; Mercaptoethanol; Mesna; Phosphoramide Mustards; Urinary Bladder | 1980 |
Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Therapy, Combination; Humans; Ifosfamide; Lung Neoplasms; Male; Mercaptoethanol; Mesna; Middle Aged; Urinary Bladder Diseases | 1983 |
Clinical overview of mesna.
Topics: Clinical Trials as Topic; Cyclophosphamide; Drug Interactions; Hematuria; Humans; Ifosfamide; Mercaptoethanol; Mesna; Neoplasms | 1983 |
Ifosfamide--current aspects and perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Humans; Ifosfamide; Kidney; Mesna | 1983 |
Therapeutic effects of single-push or fractionated injections or continuous infusion of oxazaphosphorines (cyclophosphamide, ifosfamide, Asta Z 7557).
Topics: Animals; Clinical Trials as Topic; Cyclophosphamide; Humans; Ifosfamide; Infusions, Parenteral; Kidney; Lethal Dose 50; Male; Mesna; Mice; Mice, Inbred Strains; Middle Aged; Neoplasms | 1984 |
Phase II study of ifosfamide combined with Mesna uroprotection in advanced non-small-cell lung carcinoma and other solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Neoplasms; Urinary Bladder | 1984 |
[Clinical evaluation of Mitexan in the prevention of urinary tract complications during treatment with Holoxan].
Topics: Clinical Trials as Topic; Cyclophosphamide; Cystitis; Hematuria; Humans; Ifosfamide; Mercaptoethanol; Mesna; Neoplasms | 1981 |
The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Metastasis; Neutropenia | 1995 |
Ambulatory 4-day continuous-infusion schedule of high-dose ifosfamide with mesna uroprotection and granulocyte colony-stimulating factor in advanced solid tumours: a phase I study.
Topics: Adult; Aged; Ambulatory Care; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Immunologic Factors; Infusions, Intravenous; Kidney Diseases; Male; Mesna; Middle Aged; Neoplasms; Neutropenia; Recombinant Proteins; Remission Induction; Treatment Outcome | 1995 |
High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Dacarbazine; Doxorubicin; Drug Administration Schedule; Drug Resistance; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Kidney; Male; Mesna; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Sarcoma | 1995 |
Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Double-Blind Method; Doxorubicin; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematuria; Hemoglobins; Humans; Ifosfamide; Injections, Subcutaneous; Length of Stay; Lenograstim; Leukocyte Count; Male; Mesna; Middle Aged; Nausea; Neutropenia; Platelet Count; Recombinant Proteins; Regression Analysis; Sarcoma; Soft Tissue Neoplasms; Stomatitis | 1995 |
Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Colony-Forming Units Assay; Drug Administration Schedule; Erythrocyte Transfusion; Erythropoietin; Etoposide; Female; Granulocytes; Hemoglobin A; Humans; Ifosfamide; Iron; Leukocyte Count; Lung Neoplasms; Macrophages; Male; Mesna; Middle Aged; Platelet Count; Platelet Transfusion; Recombinant Proteins; Vincristine | 1995 |
Ifosfamide plus high-dose cisplatin in patients with non-small cell lung cancer previously treated with chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Remission Induction; Survival Analysis | 1995 |
Cisplatin and ifosfamide in patients with advanced squamous cell carcinoma of the uterine cervix. A phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Ifosfamide; Mesna; Middle Aged; Survival Rate; Uterine Cervical Neoplasms | 1995 |
[Ifosfamide-induced hemorrhagic cystitis and its prevention by mesna].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Cystitis; Hemorrhage; Humans; Ifosfamide; Mesna; Methotrexate; Middle Aged; Soft Tissue Neoplasms | 1995 |
A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfamide; Infusions, Intravenous; Mesna; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Remission Induction; Salvage Therapy; Survival Analysis | 1995 |
Phase II clinical trial of carboplatin, ifosfamide, with oral mesna for metastatic breast carcinoma.
Topics: Adenocarcinoma; Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cystitis; Female; Humans; Ifosfamide; Mesna; Middle Aged; Remission Induction | 1995 |
A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: sustained efficiency and simplified administration.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Humans; Ifosfamide; Male; Mesna; Middle Aged; Neoplasms; Prospective Studies | 1995 |
A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Over Studies; Cytarabine; Etoposide; Female; Humans; Ifosfamide; Lymphoma; Male; Mesna; Methylprednisolone; Methylprednisolone Hemisuccinate; Middle Aged; Mitoxantrone; Prednisone; Salvage Therapy | 1994 |
Phase II study of ifosfamide, carboplatin, and etoposide in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Remission Induction; Survival Analysis | 1994 |
A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Feasibility Studies; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Ifosfamide; Leukopenia; Male; Mesna; Mesothelioma; Middle Aged; Peritoneal Neoplasms; Pleural Neoplasms; Remission Induction; Thrombocytopenia | 1994 |
Osteosarcoma studies at St. Jude Children's Research Hospital from 1968 through 1990.
Topics: Amputation, Surgical; Bone Neoplasms; Chemotherapy, Adjuvant; Child; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Humans; Ifosfamide; Leucovorin; Lung Neoplasms; Mesna; Osteosarcoma; Survival Analysis; Tennessee; Treatment Outcome; Vincristine | 1993 |
Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Combined Modality Therapy; Endometrial Neoplasms; Female; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Recurrence, Local | 1994 |
Synovial sarcoma. Uniform response of metastases to high dose ifosfamide.
Topics: Adolescent; Adult; Female; Humans; Ifosfamide; Infusions, Parenteral; Lung Neoplasms; Male; Mesna; Neoplasm Recurrence, Local; Sarcoma, Synovial | 1994 |
A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfamide; Mesna; Middle Aged; Mixed Tumor, Mesodermal; Organoplatinum Compounds; Ovarian Neoplasms; Time Factors | 1994 |
An ongoing randomized study of neoadjuvant chemotherapy in resectable non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Mitomycin; Mitomycins; Survival Analysis | 1994 |
Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Feasibility Studies; Female; Humans; Ifosfamide; Infusion Pumps; Infusions, Intravenous; Male; Mesna; Middle Aged; Remission Induction; Sarcoma; Soft Tissue Neoplasms | 1993 |
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dacarbazine; Doxorubicin; Female; Humans; Ifosfamide; Male; Mesna; Middle Aged; Sarcoma; Soft Tissue Neoplasms; Survival Analysis; Treatment Outcome; Urinary Bladder Diseases | 1993 |
Ifosfamide with mesna uroprotection and etoposide in recurrent, refractory acute leukemia in childhood. A Pediatric Oncology Group Study.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Child; Drug Tolerance; Etoposide; Humans; Ifosfamide; Leukemia, Myeloid; Mesna; Neoplasm Recurrence, Local; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Urinary Tract | 1993 |
Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: a phase II study of the EORTC Lung Cancer Cooperative Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Resistance; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Prognosis; Vincristine | 1993 |
Mitomycin, ifosfamide, and cisplatin in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dexamethasone; Drug Administration Schedule; Furosemide; Humans; Ifosfamide; Lung Neoplasms; Mesna; Metoclopramide; Mitomycin; Mitomycins; Nausea; Neoplasm Staging; Vomiting | 1993 |
A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Fluid Therapy; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Neutropenia; Thrombocytopenia; Vomiting | 1993 |
Ambulatory treatment with 5 days continuous venous infusion of ifosfamide for advanced colorectal cancer: a phase II feasibility study.
Topics: Adult; Aged; Ambulatory Care; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Humans; Ifosfamide; Infusion Pumps, Implantable; Infusions, Intravenous; Male; Mesna; Middle Aged | 1993 |
Ifosfamide in advanced epidermoid head and neck cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Ifosfamide; Male; Mesna; Middle Aged; Neoplasm Recurrence, Local | 1993 |
Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Female; Humans; Ifosfamide; Mesna; Middle Aged; Uterine Cervical Neoplasms | 1993 |
The addition of etoposide and ifosfamide to cisplatin as second line therapy in ovarian carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Infusions, Intravenous; Mesna; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Salvage Therapy; Treatment Outcome | 1993 |
Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Female; Humans; Ifosfamide; Mesna; Middle Aged; Uterine Cervical Neoplasms | 1993 |
A phase I study of ifosfamide with Mesna given daily for 3 consecutive days to children with malignant solid tumors.
Topics: Adolescent; Adult; Carboplatin; Child; Child, Preschool; Cisplatin; Drug Administration Schedule; Female; Humans; Ifosfamide; Infant; Male; Mesna; Neoplasms | 1993 |
A phase I study of ifosfamide given on alternate days to treat children with brain tumors.
Topics: Adolescent; Brain Neoplasms; Child; Child, Preschool; Cisplatin; Drug Administration Schedule; Female; Fluid Therapy; Humans; Hyponatremia; Ifosfamide; Leukocyte Count; Male; Mesna; Seizures | 1993 |
Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer.
Topics: Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Cystitis; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Metastasis; Remission Induction | 1995 |
Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Hemoglobins; Humans; Ifosfamide; Infusions, Intravenous; Mesna; Middle Aged; Neutropenia; Salvage Therapy; Time Factors; Vincristine | 1995 |
CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Epirubicin; Etoposide; Feasibility Studies; Female; Folic Acid; Hematologic Diseases; Humans; Ifosfamide; Karnofsky Performance Status; Lymphoma, Non-Hodgkin; Male; Mesna; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prednisolone; Remission Induction; Risk Factors; Survival Rate; Vincristine | 1996 |
A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Ifosfamide; Lymphoma; Male; Mesna; Middle Aged; Mitoxantrone; Platinum; Prospective Studies; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Treatment Failure | 1995 |
Ifosfamide and cisplatin as neoadjuvant chemotherapy for advanced cervical carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Female; Follow-Up Studies; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Staging; Prospective Studies; Radiotherapy, Adjuvant; Remission Induction; Survival Rate; Uterine Cervical Neoplasms | 1996 |
Treatment of stage III-IV non-small-cell lung carcinoma with vinorelbine in combination with ifosfamide plus MESNA: a study by the Southern Italy Oncology Group (GOIM).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Ifosfamide; Lung Neoplasms; Mesna; Middle Aged; Vinblastine; Vinorelbine | 1996 |
High-dose folinic acid and fluorouracil with or without ifosfamide is an inactive combination in advanced pancreatic cancer. A randomized phase II study of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Ifosfamide; Leucovorin; Male; Mesna; Middle Aged; Pancreatic Neoplasms | 1996 |
A combination of ifosfamide and mitoxantrone as salvage therapy in patients with advanced ovarian cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Expectorants; Female; Humans; Ifosfamide; Infusions, Intravenous; Longitudinal Studies; Mesna; Middle Aged; Mitoxantrone; Ovarian Neoplasms; Salvage Therapy; World Health Organization | 1996 |
Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Sarcoma, Endometrial Stromal | 1996 |
Ifosfamide-based combination chemotherapy in advanced non-small cell lung cancer: two phase I studies.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Tolerance; Expectorants; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Remission Induction; Survival Rate; Vinblastine; Vinorelbine | 1996 |
Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Drug Tolerance; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Leukocyte Count; Male; Mesna; Middle Aged; Neoplasms; Neutropenia; Neutrophils; Paclitaxel; Recombinant Proteins; Remission Induction | 1996 |
Phase II evaluation of ifosfamide/mesna in metastatic prostate cancer. A Southwest Oncology Group study.
Topics: Adenocarcinoma; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Follow-Up Studies; Humans; Ifosfamide; Injections, Intravenous; Leukopenia; Male; Mesna; Neurologic Examination; Prostatic Neoplasms; Remission Induction; Survival Rate | 1996 |
A phase II study of ifosfamide in recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Alkylating; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Ifosfamide; Infusions, Intravenous; Injections, Intravenous; Male; Mesna; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Survival Rate | 1996 |
A phase II study of cisplatin/ifosfamide in recurrent/metastatic undifferentiated nasopharyngeal carcinoma among young blacks in southern Africa.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Black People; Bone Neoplasms; Carcinoma; Cisplatin; Disease Progression; Female; Humans; Ifosfamide; Male; Mesna; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neutropenia; Remission Induction; South Africa; Survival Rate | 1996 |
Response of pediatric malignant solid tumors following ifosfamide or ifosfamide/carboplatin/etoposide: a single hospital experience.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Etoposide; Female; Humans; Ifosfamide; Male; Mesna; Neoplasms | 1996 |
A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged | 1996 |
Ifosfamide, mesna and epirubicin as second-line chemotherapy in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Staging; Remission Induction; Salvage Therapy | 1996 |
Oral ifosfamide/mesna versus intravenous ifosfamide/mesna in non-small-cell lung cancer: a randomized phase II trial of the EORTC lung cancer cooperative group.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Ifosfamide; Infusions, Intravenous; Lung Neoplasms; Male; Mesna; Middle Aged | 1996 |
A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Endometrial Neoplasms; Female; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome | 1996 |
Combination chemotherapy for advanced bilharzial bladder carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Male; Mesna; Middle Aged; Schistosomiasis; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms; Vincristine | 1996 |
Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Carboplatin; Carcinoma, Small Cell; Cyclophosphamide; Disease Progression; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Multivariate Analysis; Survival Analysis; Vincristine | 1996 |
Ifosfamide and vinorelbine as first-line chemotherapy for advanced non-small cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Brain; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Expectorants; Female; Humans; Ifosfamide; Leukopenia; Lung Neoplasms; Male; Mesna; Middle Aged; Neoplasm Staging; Peripheral Nerves; Phlebitis; Remission Induction; Survival Rate; Treatment Failure; Vinblastine; Vinorelbine | 1996 |
GM-CSF did not allow doxorubicin dose escalation in the MAID regimen: a phase I trial. A Southwest Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Dacarbazine; Doxorubicin; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Ifosfamide; Leukopenia; Mesna; Recombinant Proteins; Sarcoma; Treatment Failure | 1996 |
Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged | 1997 |
High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Male; Mesna; Middle Aged; Pilot Projects; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome | 1997 |
Can molgramostim enhance the antitumor effects of cytotoxic drugs in patients with advanced sarcomas?
Topics: Adult; Antineoplastic Agents; Cisplatin; Doxorubicin; Drug Synergism; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Ifosfamide; Mesna; Mitomycins; Recombinant Proteins; Sarcoma; Survival Analysis | 1997 |
Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer.
Topics: Administration, Oral; Aged; Alopecia; Ambulatory Care; Antineoplastic Agents, Alkylating; Bone Marrow; Carcinoma, Transitional Cell; Cause of Death; Disease Progression; Drug Administration Schedule; Expectorants; Feasibility Studies; Female; Humans; Ifosfamide; Infusions, Intravenous; Lymphatic Metastasis; Male; Mesna; Middle Aged; Nausea; Neoplasm Staging; Remission Induction; Survival Rate; Urinary Bladder Neoplasms; Vomiting | 1997 |
Combination salvage chemotherapy with MIZE (ifosfamide-mesna, idarubicin and etoposide) for relapsing or refractory lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Idarubicin; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Recurrence; Salvage Therapy | 1997 |
Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Infusions, Intravenous; Male; Mesna; Middle Aged; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome | 1997 |
A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms; Paclitaxel | 1998 |
Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Cross-Over Studies; Humans; Ifosfamide; Infusions, Intravenous; Lung Neoplasms; Male; Mesna; Middle Aged | 1998 |
A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Female; Humans; Ifosfamide; Male; Mesna; Middle Aged; Osteosarcoma; Rhabdomyosarcoma; Sarcoma, Ewing; Survival Rate; Treatment Outcome | 1998 |
High-dose-intensity combination chemotherapy for advanced sarcomas: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Dacarbazine; Doxorubicin; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Tests; Humans; Ifosfamide; Infusions, Intravenous; Male; Mesna; Middle Aged; Neutropenia; Pilot Projects; Recombinant Proteins; Sarcoma | 1998 |
Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Hypoxia; Disease-Free Survival; Dose-Response Relationship, Drug; Etanidazole; Etoposide; Expectorants; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Infusions, Intravenous; Male; Mesna; Middle Aged; Neoplasms; Recurrence; Survival Rate | 1998 |
Alternating triple therapy for the treatment of intermediate grade and immunoblastic lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin; Male; Mesna; Methotrexate; Methylprednisolone Hemisuccinate; Middle Aged; Mitoxantrone; Prednisone; Prognosis; Vincristine | 1998 |
Phase II study of ifosfamide and mesna in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Female; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Metastasis; Remission Induction | 1998 |
Phase II trial of MINE as a front-line therapeutic modality in intermediate- and high-grade non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Mitoxantrone; Prospective Studies; Treatment Outcome | 1998 |
Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy.
Topics: Administration, Oral; Adult; Aged; Antidotes; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Expectorants; Female; Humans; Ifosfamide; Injections, Intravenous; Male; Mesna; Methylene Blue; Middle Aged | 1998 |
High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible?
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Infusions, Intravenous; Male; Mesna; Middle Aged; Neutropenia; Sarcoma; Soft Tissue Neoplasms; Thrombocytopenia | 1998 |
[Chemotherapy of resistant and recurrent lymphoma based on a combination of ifosfamide and etoposide. Antitumor effects, toxicity and stimulation of peripheral stem cells].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Leukapheresis; Lymphoma, Non-Hodgkin; Male; Mesna; Methotrexate; Middle Aged; Mitoxantrone; Recurrence; Salvage Therapy; Transplantation Conditioning | 1998 |
Local host response in osteosarcoma after chemotherapy referred to radiographs, CT, tumour necrosis and patient survival.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cisplatin; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Infant; Infant, Newborn; Male; Mesna; Methotrexate; Middle Aged; Necrosis; Neoadjuvant Therapy; Osteosarcoma; Predictive Value of Tests; Prognosis; Tomography, X-Ray Computed | 1998 |
Phase II study with ifosfamide, carboplatin, etoposide (ICE regimen) at intermediate dosage for advanced non small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Survival Analysis; Treatment Outcome | 1998 |
Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Methylprednisolone; Middle Aged; Mitoxantrone; Paclitaxel; Prospective Studies; Recurrence; Remission Induction; Survival Rate; Treatment Outcome | 1998 |
A brief intensive cisplatin-based outpatient chemotherapy regimen with filgrastim and megestrol acetate support for advanced non-small cell lung cancer: results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite Stimulants; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Male; Megestrol Acetate; Mesna; Middle Aged; Protective Agents; Recombinant Proteins; Survival Analysis; Treatment Outcome | 1998 |
Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Mesna; Middle Aged; Ovarian Neoplasms; Palliative Care; Prognosis; Survival Analysis | 1999 |
Phase I-II trial of intensification of the MAID regimen with support of lenograstim (rHuG-CSF) in patients with advanced soft-tissue sarcoma (STS).
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lenograstim; Male; Mesna; Middle Aged; Recombinant Proteins; Sarcoma; Survival Analysis | 1999 |
A phase II study of a three-drug combination (cisplatin, ifosfamide and vinorelbine) plus granulocyte-colony stimulating factor in advanced non small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Injections, Subcutaneous; Lung Neoplasms; Male; Mesna; Middle Aged; Protective Agents; Treatment Outcome; Vinblastine | 1999 |
Role of chemotherapy in the treatment of infantile fibrosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Dactinomycin; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fibrosarcoma; Humans; Ifosfamide; Infant; Infant, Newborn; Male; Mesna; Soft Tissue Neoplasms; Vincristine | 1999 |
WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bone Neoplasms; Child; Cyclophosphamide; Cysteine; Female; Humans; Ifosfamide; Infusions, Intravenous; Kinetics; Male; Mesna; Radiation-Protective Agents; Sarcoma, Ewing; Sulfhydryl Compounds; Time Factors | 1999 |
Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK).
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Dose-Response Relationship, Drug; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Ifosfamide; Male; Mesna; Middle Aged; Prodrugs; Protective Agents; Remission Induction; Sarcoma; Time Factors | 1999 |
Phase II study of ifosfamide plus vinorelbine in metastatic breast cancer patients previously treated with combination chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Infusions, Intravenous; Mesna; Middle Aged; Neoplasm Metastasis; Treatment Outcome; Vinblastine; Vinorelbine | 1999 |
Ifosfamide and vinorelbine in metastatic breast cancer in patients with prior anthracycline therapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Infusions, Intravenous; Mesna; Middle Aged; Neoplasm Metastasis; Neutropenia; Prospective Studies; Treatment Outcome; Vinblastine; Vinorelbine | 1999 |
Dose-intense salvage therapy after neoadjuvant chemotherapy: feasibility and preliminary results.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphatic Metastasis; Melphalan; Mesna; Middle Aged; Pilot Projects; Salvage Therapy; Tegafur; Thiotepa; Vinblastine; Vinorelbine | 1999 |
Very intensive, short-term chemotherapy for children and adolescents with metastatic sarcomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Child; Child, Preschool; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Infant; Male; Mesna; Mouth Mucosa; Neoplasm Metastasis; Neutropenia; Prospective Studies; Remission Induction; Sarcoma; Stomatitis; Time Factors; Treatment Outcome; Vincristine | 2000 |
Dose- intensified, preoperative and adjuvant chemotherapy in patients with T3- and T4- breast cancer: toxicity, clinical and pathological remission.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Immunohistochemistry; Mastectomy; Mesna; Middle Aged; Neoplasm Staging; Paclitaxel; Pilot Projects; Protective Agents; Recombinant Proteins; Survival Analysis; Tamoxifen; Treatment Outcome | 1999 |
Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Mitoxantrone; Paclitaxel; Recurrence; Taxoids; Time Factors; Treatment Outcome | 1999 |
[High-dose ifosfamide in patients with stage IV non-small cell lung cancer: phase II trial from the Groupe français de pneumo-cancérologie (GFPC)].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Survival Analysis; Treatment Outcome | 1999 |
Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione.
Topics: Acetaldehyde; Antineoplastic Agents, Alkylating; Cysteine; Dose-Response Relationship, Drug; Glutathione; Homocysteine; Humans; Ifosfamide; Infusions, Intravenous; Leukocytes; Mesna; Neoplasms; Oxidation-Reduction; Protective Agents; Sulfhydryl Compounds | 2000 |
High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Carcinoma; Combined Modality Therapy; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Mesna; Middle Aged; Ovarian Neoplasms; Recombinant Proteins; Transplantation, Autologous | 2000 |
Neoadjuvant chemotherapy with ifosfamide, cisplatin, and vinorelbine in advanced squamous cell carcinoma of the cervix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Ifosfamide; Mesna; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Survival Analysis; Uterine Cervical Neoplasms; Vinblastine | 2000 |
Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: a randomized phase II trial in small-cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Platelet Count; Quality of Life | 2001 |
Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Ifosfamide; Male; Mesna; Middle Aged; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome | 2001 |
Radiation induced chemotherapy sensitization in trimodality therapy of stage III non small cell lung cancer. A preliminary report.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Humans; Ifosfamide; Lomustine; Lung Neoplasms; Mesna; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Time Factors | 2000 |
Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Ifosfamide; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin; Mesna; Methylprednisolone Hemisuccinate; Middle Aged; Mitoxantrone; Prednisone; Retrospective Studies; Salvage Therapy; Vincristine | 2001 |
Combination chemotherapy for extensive small cell lung cancer -- experience from India.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Drug Administration Schedule; Drug Costs; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; India; Lung Neoplasms; Male; Mesna; Middle Aged; Patient Compliance; Poverty; Survival Analysis; Survival Rate; Treatment Outcome; Vincristine | 2001 |
Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Kinetics; Lymphoma; Male; Mesna; Methotrexate; Middle Aged; Mitoxantrone; Prognosis; Salvage Therapy; Treatment Outcome | 2001 |
Anticipated administration of GM-CSF in the treatment of non small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Mitomycin; Recombinant Proteins; Survival Rate | 2001 |
Ifosfamide, paclitaxel and cisplatin first-line chemotherapy in advanced, suboptimally debulked epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Cisplatin; Female; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Survival Analysis | 2001 |
Ifosfamide and vinorelbine in advanced platinum-resistant ovarian cancer: excessive toxicity with a potentially active regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Mesna; Middle Aged; Neutropenia; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Vinblastine; Vinorelbine | 2002 |
Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Doxorubicin; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Ifosfamide; Infusions, Intravenous; Injections, Subcutaneous; Leukopenia; Male; Mesna; Middle Aged; Mitomycin; Neoadjuvant Therapy; Sarcoma; Soft Tissue Neoplasms; Thrombocytopenia; Treatment Outcome; Vomiting | 2002 |
Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Ifosfamide; Male; Mesna; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2002 |
Outcome of B-cell non-Hodgkin lymphoma protocol CCCG-B NHL97: a report from Chinese multi-center cooperative group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; China; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Infant; Lymphoma, B-Cell; Male; Mesna; Methotrexate; Prednisone; Treatment Outcome; Vincristine | 2002 |
Mitoxantrone/ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Etoposide; Female; Humans; Ifosfamide; Lymphoma; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Mitoxantrone; Polymerase Chain Reaction; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Stem Cells; Time Factors | 2002 |
[Preliminary result of advanced soft tissue sarcoma treated by MAID regimen].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Female; Humans; Ifosfamide; Infusions, Intravenous; Leukopenia; Male; Mesna; Middle Aged; Nausea; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome; Vomiting | 2002 |
Outpatient intensive chemotherapy for small cell lung cancer: five years experience of modified 'ICE' ifosfamide carboplatin and etoposide.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Outpatients; Prognosis; Survival | 2002 |
Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Doxorubicin; Extremities; Female; Humans; Ifosfamide; Male; Mesna; Middle Aged; Neoadjuvant Therapy; Radiotherapy; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome | 2003 |
High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Disease-Free Survival; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Male; Mesna; Mesothelioma; Middle Aged; Pleural Neoplasms; Protective Agents; Recombinant Proteins; Treatment Outcome | 2003 |
A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Ifosfamide; Immunohistochemistry; Mesna; Middle Aged; Mixed Tumor, Mullerian; Receptor, ErbB-2; Receptor, Platelet-Derived Growth Factor beta; Receptors, Estrogen; Receptors, Progesterone; Uterine Neoplasms | 2003 |
Dose finding of ifosfamide administered with a chronic two-week continuous infusion.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Drug Administration Schedule; Female; Humans; Ifosfamide; Infusions, Intravenous; Male; Mesna; Middle Aged; Protective Agents | 2003 |
Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion.
Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Carboplatin; Chromatography, High Pressure Liquid; Cysteine; Female; Half-Life; Humans; Ifosfamide; Male; Mesna; Metabolic Clearance Rate; Middle Aged; Models, Biological; Neoplasms; Protective Agents | 2003 |
Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Cross-Over Studies; Female; Humans; Ifosfamide; Infusions, Intravenous; Male; Mesna; Middle Aged; Prospective Studies; Protective Agents; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome | 2003 |
A pilot study of CODOX-M/IVAC in primary refractory or relapsed high-grade non-Hodgkin's lymphoma. A Scotland and Newcastle Lymphoma Group Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Injections, Spinal; Lenograstim; Leucovorin; Lymphoma, Non-Hodgkin; Male; Mesna; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Pilot Projects; Prognosis; Recombinant Proteins; Salvage Therapy; Sepsis; Treatment Outcome; Vincristine | 2003 |
Two schedules of application for mesna and their influence on the thiol-metabolism.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Epirubicin; Etoposide; Humans; Ifosfamide; Infusions, Intravenous; Injections, Intravenous; Mesna; Neoplasms; Protective Agents; Sulfhydryl Compounds | 2003 |
Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Leucovorin; Mesna; Methotrexate; Middle Aged; Survival Analysis; Treatment Outcome; Vincristine | 2004 |
Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Female; Humans; Ifosfamide; Infusions, Intravenous; Male; Mesna; Neoplasms; Protective Agents | 2004 |
Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacteremia; Bone Marrow Neoplasms; Child; Child, Preschool; Cytarabine; Dexamethasone; Etoposide; Female; Flow Cytometry; Humans; Idarubicin; Ifosfamide; Infant; Infusions, Intravenous; Leucovorin; Male; Mesna; Methotrexate; Mouth Mucosa; Polyethylene Glycols; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Stomatitis; Thioguanine; Treatment Outcome; Vincristine | 2004 |
Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cohort Studies; Extremities; Humans; Ifosfamide; Mesna; Middle Aged; Proportional Hazards Models; Prospective Studies; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Survival Analysis; Time Factors; Treatment Outcome | 2004 |
Long-term results of dose density therapy in patients with aggressive lymphoma.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cyclophosphamide; Dexamethasone; Epirubicin; Etoposide; Humans; Ifosfamide; Longitudinal Studies; Lymphoma; Mesna; Methotrexate; Middle Aged; Prednisone; Survival Analysis; Treatment Failure; Treatment Outcome; Vincristine | 2005 |
Ifosfamide, mesna, and interferon-alpha2A combination chemoimmunotherapy in malignant mesothelioma: results of a single center in central anatolia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Humans; Ifosfamide; Infusions, Intravenous; Interferon alpha-2; Interferon-alpha; Male; Mesna; Mesothelioma; Middle Aged; Neutropenia; Recombinant Proteins; Survival Analysis; Treatment Outcome | 2004 |
High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Ifosfamide; Infusions, Intravenous; Male; Mesna; Middle Aged; Sarcoma; Treatment Outcome | 2004 |
Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Male; Mesna; Neoadjuvant Therapy; Protective Agents; Sarcoma; Soft Tissue Neoplasms; Survival Analysis; Treatment Outcome; Vincristine | 2005 |
A phase I study of prolonged ambulatory infusion of Ifosfamide with oral mesna.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Agents, Alkylating; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Ifosfamide; Infusions, Intravenous; Male; Mesna; Middle Aged; Neoplasms; Protective Agents | 2005 |
Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514.
Topics: Adult; Aged; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Doxorubicin; Extremities; Female; Humans; Ifosfamide; Male; Mesna; Middle Aged; Neoadjuvant Therapy; Radiotherapy, Adjuvant; Risk Assessment; Sarcoma; Survival Analysis; Treatment Failure; Treatment Outcome | 2006 |
Ifosfamide/mesna as salvage therapy in platinum pretreated ovarian cancer patients--long-term results of a phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfamide; Mesna; Middle Aged; Ovarian Neoplasms; Platinum Compounds; Protective Agents; Salvage Therapy; Survival Analysis; Treatment Outcome | 2006 |
Results of a phase II clinical trial on the use of ifosfamide for treatment of cats with vaccine-associated sarcomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Cat Diseases; Cats; Drug Administration Schedule; Female; Ifosfamide; Male; Mesna; Sarcoma; Sodium Chloride; Vaccines | 2006 |
Full-dose ifosfamide can be safely administered to outpatients.
Topics: Adolescent; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dactinomycin; Dose-Response Relationship, Drug; Humans; Ifosfamide; Infant; Mesna; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Vincristine | 2008 |
Histological changes in bladders of patients submitted to ifosfamide chemotherapy even with mesna prophylaxis.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Cystoscopy; Edema; Erythrocytes; Etoposide; Exocytosis; Female; Hemorrhage; Humans; Ifosfamide; Male; Mesna; Middle Aged; Urinary Bladder; Urinary Bladder Diseases; Urothelium | 2007 |
A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Female; Humans; Ifosfamide; Mesna; Middle Aged; Mixed Tumor, Mesodermal; Neoplasm Staging; Ovarian Neoplasms; Pilot Projects | 2007 |
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Humans; Hysterectomy; Ifosfamide; Incidence; Mesna; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Protective Agents; Radiotherapy, Adjuvant; Risk Factors; Survival Analysis; Treatment Failure; Treatment Outcome; Uterine Neoplasms | 2007 |
Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Chromatography, High Pressure Liquid; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mesna; Metabolic Clearance Rate; Middle Aged; Prognosis; Proportional Hazards Models; Small Cell Lung Carcinoma | 2008 |
Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Metastasis; Paclitaxel; Uterine Cervical Neoplasms | 2009 |
Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Administration Schedule; Female; Humans; Ifosfamide; Infusion Pumps; Male; Mesna; Middle Aged; Nausea; Outpatients; Pilot Projects; Sarcoma; Survival Analysis; Time Factors; Treatment Outcome; Vomiting | 2010 |
Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Modality Therapy; Disease Progression; Doxorubicin; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunoenzyme Techniques; Male; Melphalan; Mesna; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroectodermal Tumors, Primitive, Peripheral; Osteosarcoma; Prognosis; Prospective Studies; Protective Agents; Remission Induction; Rhabdomyosarcoma; Safety; Sarcoma; Sarcoma, Ewing; Survival Rate; Transplantation, Autologous; Treatment Outcome; Young Adult | 2009 |
Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fever; Follow-Up Studies; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Mitoxantrone; Peripheral Nervous System Diseases; Prednisolone; Prospective Studies; Radiotherapy, Adjuvant; Remission Induction; Treatment Outcome; Vincristine | 2010 |
Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Brain Injuries; Canada; Cerebral Infarction; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Ifosfamide; Male; Maximum Tolerated Dose; Mesna; Middle Aged; Neoplasms; Neutropenia; Taxoids; Thrombocytopenia | 2010 |
High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Consolidation Chemotherapy; Dacarbazine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Mesna; Middle Aged; Peripheral Blood Stem Cell Transplantation; Sarcoma; Young Adult | 2012 |
Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Combined Modality Therapy; DNA Topoisomerases, Type I; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Mesna; Metabolic Clearance Rate; Middle Aged; Mucositis; Multivariate Analysis; Neoplasms; Proportional Hazards Models; Topotecan; Transplantation, Autologous; Treatment Outcome | 2011 |
Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Doxorubicin; Extremities; Female; Follow-Up Studies; Humans; Ifosfamide; Male; Mesna; Middle Aged; Neoadjuvant Therapy; Radiotherapy, Adjuvant; Sarcoma; Survival Rate; Treatment Outcome | 2012 |
Treatment of Burkitt lymphoma in equatorial Africa using a simple three-drug combination followed by a salvage regimen for patients with persistent or recurrent disease.
Topics: Adolescent; Adult; Africa South of the Sahara; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cause of Death; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Mesna; Methotrexate; Middle Aged; Neoplasm Staging; Recurrence; Remission Induction; Risk; Salvage Therapy; Survival Rate; Treatment Outcome; Vincristine; Young Adult | 2012 |
Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Doxorubicin; Extremities; Female; Follow-Up Studies; Humans; Ifosfamide; Male; Mesna; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Sarcoma; Survival Rate; Time Factors; Young Adult | 2013 |
Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: influence of sex and age.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Ifosfamide; Male; Melphalan; Mesna; Neoplasm Staging; Prognosis; Prospective Studies; Sarcoma, Ewing; Sex Factors; Survival Rate; Vincristine; Young Adult | 2014 |
Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B-Cell Activating Factor; Bone Marrow; Chemokine CXCL12; Drug Resistance, Neoplasm; Etoposide; Female; Filgrastim; Gene Expression Regulation, Leukemic; Humans; Ifosfamide; Interleukin-7; Male; Mesna; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Osteocalcin; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Stem Cell Niche; Tumor Microenvironment; Young Adult | 2015 |
Clinical Outcome of Neoadjuvant Radiochemotherapy in Locally Advanced Cervical Cancer: Results of an Open Prospective, Multicenter Phase 2 Study of the North-Eastern German Society of Gynecological Oncology.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Hysterectomy; Ifosfamide; Mesna; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prospective Studies; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms | 2017 |
Neoadjuvant Interdigitated Chemoradiotherapy Using Mesna, Doxorubicin, and Ifosfamide for Large, High-grade, Soft Tissue Sarcomas of the Extremity: Improved Efficacy and Reduced Toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arm; Chemoradiotherapy; Doxorubicin; Female; Humans; Ifosfamide; Leg; Male; Mesna; Middle Aged; Neoadjuvant Therapy; Organ Sparing Treatments; Retrospective Studies; Sarcoma; Treatment Outcome | 2019 |
298 other study(ies) available for ifosfamide and mesna
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
[Antidote against the urotoxic effects of the oxazaphorine derivatives cyclophosphamide, ifosfamide and trofosfamide].
Topics: Animals; Antidotes; Carcinosarcoma; Cyclophosphamide; Ifosfamide; Mercaptoethanol; Mesna; Phosphoramide Mustards; Rats; Urine | 1979 |
[Prevention of urinary tract toxicity of oxazaphosphorines by a "uroprotector". Report on a field study (author's transl)].
Topics: Adolescent; Adult; Aged; Bronchial Neoplasms; Child; Cyclophosphamide; Female; Gastrointestinal Diseases; Hematuria; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; Middle Aged; Ovarian Neoplasms; Phosphoramide Mustards; Testicular Neoplasms | 1979 |
Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide.
Topics: Acrolein; Aldehydes; Animals; Cyclophosphamide; Cystitis; Female; Ifosfamide; Inactivation, Metabolic; Kidney; Male; Mesna; Rats; Urinary Bladder; Urinary Tract; Urologic Diseases | 1979 |
[High-dose ifosfamide therapy: systemic use of a mucolytic agent for the reduction of urotoxicity].
Topics: Adult; Cyclophosphamide; Cystitis; Hematuria; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; Osteosarcoma | 1979 |
Phase II study of cisplatin, ifosfamide with mesna, and etoposide (PIE) chemotherapy for advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Clinical Protocols; Clinical Trials, Phase II as Topic; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Remission Induction; Survival Rate | 1992 |
Serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Ifosfamide; L-Lactate Dehydrogenase; Lung Neoplasms; Male; Mesna; Middle Aged; Phosphopyruvate Hydratase; Probability; Prospective Studies; Remission Induction; Survival Rate | 1992 |
Oral ifosfamide-mesna: a clinical investigation in advanced non-small-cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Dreams; Drug Administration Schedule; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Neoplasm Staging; Remission Induction; Sleep Wake Disorders | 1992 |
Non-Hodgkin's lymphomas: a review of the M.D. Anderson experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Clinical Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Mesna; Methylprednisolone; Middle Aged; Mitoxantrone; Prednisone; Salvage Therapy; Texas; Vincristine | 1992 |
Uroepithelial and nephrotubular toxicity in patients receiving ifosfamide/mesna: measurement of urinary N-acetyl-beta-D-glucosaminidase and beta-2-microglobulin.
Topics: Acetylglucosaminidase; Adult; Aged; beta 2-Microglobulin; Creatinine; Female; Humans; Ifosfamide; Kidney Diseases; Male; Mesna; Middle Aged; Neoplasms | 1992 |
Comparison of N-acetylcysteine and mesna as uroprotectors with ifosfamide combination chemotherapy in refractory germ cell tumors.
Topics: Acetylcysteine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dysgerminoma; Etoposide; Hematuria; Humans; Ifosfamide; Male; Mesna; Severity of Illness Index; Vinblastine | 1992 |
Encephalopathy in ifosfamide-treated patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Diseases; Female; Humans; Ifosfamide; Male; Mesna; Middle Aged; Neoplasms; Neurologic Examination; Substance-Related Disorders; Tomography, X-Ray Computed | 1992 |
Chemotherapy for hepatic angiosarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Hemangiosarcoma; Humans; Ifosfamide; Liver Neoplasms; Male; Mesna; Tomography, X-Ray Computed | 1992 |
Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Agranulocytosis; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Ifosfamide; Leiomyosarcoma; Mesna; Middle Aged; Remission Induction; Uterine Neoplasms | 1992 |
Primary tumour mutant p53 gene protein and epidermal growth factor receptor expression and doxorubicin plus ifosfamide for recurrent breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; ErbB Receptors; Female; Gene Expression; Genes, p53; Humans; Ifosfamide; Mesna; Mutation; Prognosis; Retrospective Studies; Tumor Suppressor Protein p53 | 1992 |
Epidermal growth factor receptors and doxorubicin plus ifosfamide/mesna in recurrent breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; ErbB Receptors; Female; Humans; Ifosfamide; Mesna; Neoplasm Recurrence, Local | 1991 |
Chemotherapy in recurrent and advanced cervical cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Ifosfamide; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Mesna; Middle Aged; Neoplasm Recurrence, Local; Uterine Cervical Neoplasms | 1991 |
Chemotherapy in perineal leiomyosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedule; Female; Humans; Ifosfamide; Leiomyosarcoma; Mesna; Middle Aged; Perineum; Soft Tissue Neoplasms; Vincristine | 1992 |
Ifosfamide with mesna in squamous carcinoma of the cervix: phase II results in patients with advanced or recurrent disease.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Drug Evaluation; Drug Therapy, Combination; Female; Hematologic Diseases; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Recurrence, Local; Nervous System Diseases; Uterine Cervical Neoplasms | 1991 |
Etoposide (VP-16), ifosfamide/mesna, and cisplatin chemotherapy for advanced and recurrent carcinoma of the cervix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Etoposide; Female; Hematologic Diseases; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Recurrence, Local; Uterine Cervical Neoplasms | 1991 |
Ifosfamide, methotrexate and 5-fluorouracil for pretreated advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; Hematopoiesis; Humans; Ifosfamide; Liver Neoplasms; Mesna; Methotrexate; Middle Aged; Risk Factors; Survival Analysis | 1991 |
Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Drug Stability; Epirubicin; Etoposide; Feasibility Studies; Female; Humans; Ifosfamide; Infusion Pumps, Implantable; Infusions, Intravenous; Male; Mesna; Middle Aged; Mitoxantrone; Neoplasms | 1991 |
The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump.
Topics: Ambulatory Care; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Stability; Humans; Ifosfamide; Infusion Pumps; Mesna; Solutions; Temperature | 1991 |
Chemotherapy with high dose ifosfamide/mesna plus cisplatin for the treatment of ovarian cancer: a study of the Grupo de Estudio y Tratamiento Latino-Americano del Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Survival Rate | 1991 |
Phase II study of ifosfamide with mesna in adult patients with recurrent diffuse astrocytoma.
Topics: Adolescent; Adult; Aged; Astrocytoma; Blood Cell Count; Brain Neoplasms; Drug Evaluation; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds | 1991 |
Experience with salvage regimens at M.D. Anderson Hospital.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Evaluation; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Lymphoma; Lymphoma, Non-Hodgkin; Mesna; Methotrexate; Methylprednisolone; Methylprednisolone Hemisuccinate; Mitoguazone; Mitoxantrone; Remission Induction; Survival Rate | 1991 |
Ifosfamide by continuous infusion to prevent encephalopathy.
Topics: Brain Diseases; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Humans; Ifosfamide; Infusions, Intravenous; Mesna | 1990 |
Ifosfamide pharmacokinetics and neurotoxicity.
Topics: Adult; Central Nervous System Diseases; Drug Administration Schedule; Drug Therapy, Combination; Humans; Ifosfamide; Infusions, Intravenous; Liver; Mesna; Middle Aged; Retrospective Studies | 1990 |
High-dose ifosfamide with mesna uroprotection: a phase I study.
Topics: Blood; Bone Marrow; Central Nervous System; Dose-Response Relationship, Drug; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Humans; Ifosfamide; Kidney; Mercaptoethanol; Mesna; Neoplasms; Remission Induction; Time Factors; Urinary Tract | 1990 |
False-positive ketone tests: a bedside measure of urinary mesna.
Topics: Adolescent; Child; False Positive Reactions; Female; Humans; Ifosfamide; Ketones; Mercaptoethanol; Mesna | 1990 |
[Effects of mesna (2-mercaptoethane sodium sulfonate) in children with malignant disease receiving oxazaphosphorine chemotherapy].
Topics: Bone Neoplasms; Child; Cyclophosphamide; Cystitis; Female; Hematuria; Humans; Ifosfamide; Leukemia; Lymphoma, Non-Hodgkin; Male; Mercaptoethanol; Mesna; Neuroblastoma; Osteosarcoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rhabdomyosarcoma | 1990 |
Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Doxorubicin; Drug Evaluation; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Remission Induction; Sarcoma; Survival Rate | 1990 |
Phase II study of doxorubicin plus ifosfamide/mesna in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Evaluation; ErbB Receptors; Female; Humans; Ifosfamide; Mesna; Middle Aged; Survival Rate | 1990 |
Interstitial pneumonitis associated with ifosfamide therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Female; Humans; Ifosfamide; Lung Neoplasms; Mesna; Middle Aged; Pulmonary Fibrosis; Sarcoma | 1990 |
Ifosfamide and mesna at high doses for the treatment of cancer of the cervix: a GETLAC study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Humans; Ifosfamide; Mercaptoethanol; Mesna; Middle Aged; Uterine Cervical Neoplasms | 1990 |
Ifosfamide given as a 24-h infusion with mesna in patients with recurrent ovarian cancer: preliminary results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfamide; Infusions, Intravenous; Mercaptoethanol; Mesna; Neoplasm Recurrence, Local; Ovarian Neoplasms | 1990 |
Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies.
Topics: Antineoplastic Agents; Carcinoma; Drug Evaluation; Female; Humans; Ifosfamide; Mercaptoethanol; Mesna; Middle Aged; Ovarian Neoplasms; Sarcoma; Uterine Cervical Neoplasms | 1990 |
Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Ifosfamide; Mercaptoethanol; Mesna; Middle Aged | 1990 |
Ifosfamide/etoposide and mesna uroprotection in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Etoposide; Female; Humans; Ifosfamide; Mesna; Middle Aged | 1990 |
High-dose ifosfamide and mesna in advanced breast cancer. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Female; Humans; Ifosfamide; Mercaptoethanol; Mesna; Middle Aged | 1990 |
Combined high-dose carboplatin and cisplatin, and ifosfamide in previously untreated ovarian cancer patients with residual disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Drug Evaluation; Female; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms | 1990 |
Cyclophosphamide and ifosfamide: role of uroprotective agents.
Topics: Acetylcysteine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Hematuria; Humans; Ifosfamide; Mercaptoethanol; Mesna; Urogenital Neoplasms | 1990 |
[Ifosfamide-induced urinary bladder lesion and its inhibition by mesna].
Topics: Animals; Cystitis; Dose-Response Relationship, Drug; Female; Ifosfamide; Injections, Intravenous; Male; Mesna; Neoplasms, Experimental; Rats; Rats, Inbred Strains; Time Factors | 1990 |
Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Drug Evaluation; Etoposide; Female; Humans; Hyperthermia, Induced; Ifosfamide; Male; Mesna; Middle Aged; Regression Analysis; Sarcoma; Soft Tissue Neoplasms | 1990 |
Bioavailability of subcutaneous ifosfamide and feasibility of continuous outpatient application in cancer patients.
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Drug Administration Schedule; Feasibility Studies; Female; Humans; Hydrogen-Ion Concentration; Ifosfamide; Infusion Pumps, Implantable; Infusions, Intravenous; Injections, Subcutaneous; Male; Mesna; Middle Aged; Pancreatic Neoplasms; Sarcoma; Soft Tissue Neoplasms | 1990 |
Chemotherapy of metastatic soft tissue sarcoma with a combination of adriamycin and DTIC or adriamycin and ifosfamide.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Dose-Response Relationship, Drug; Doxorubicin; Female; Follow-Up Studies; Humans; Ifosfamide; Male; Mesna; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Survival Rate | 1990 |
Intravenous infusions of ifosfamide/mesna and perturbation of warfarin anticoagulant control.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation; Blood Coagulation Disorders; Drug Interactions; Drug Synergism; Female; Humans; Ifosfamide; Infusions, Intravenous; Male; Mesna; Middle Aged; Warfarin | 1990 |
Chemotherapeutic approach to uterine papillary serous carcinoma.
Topics: Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Cisplatin; Combined Modality Therapy; Doxorubicin; Female; Humans; Ifosfamide; Mesna; Middle Aged; Peptides; Tissue Polypeptide Antigen; Uterine Neoplasms | 1990 |
Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluation; Female; Humans; Ifosfamide; Leukopenia; Male; Mesna; Middle Aged; Sarcoma; Soft Tissue Neoplasms; Thrombocytopenia | 1990 |
Ifosfamide and mesna with doxorubicin have activity in malignant mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Ifosfamide; Mesna; Mesothelioma | 1990 |
Dose-finding studies with carboplatin, ifosfamide, etoposide, and mesna in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Organoplatinum Compounds; Survival Rate | 1990 |
Ifosfamide with mesna uroprotection in the management of lung cancer.
Topics: Aged; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mercaptoethanol; Mesna; Middle Aged; Survival Rate; Urologic Diseases; Vincristine | 1990 |
Malignant fibrous histiocytoma of the fallopian tube.
Topics: Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Fallopian Tube Neoplasms; Female; Histiocytoma, Benign Fibrous; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Recurrence, Local | 1990 |
Ifosfamide and mesna in combination with other cytostatic drugs in the treatment of patients with advanced cancer.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Leukopenia; Lung Neoplasms; Male; Mesna; Middle Aged; Nausea; Ovarian Neoplasms; Sarcoma, Ewing; Testicular Neoplasms; Vomiting | 1990 |
Drug-induced encephalopathy after previous ifosfamide treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Central Nervous System Diseases; Female; Humans; Ifosfamide; Mesna; Middle Aged | 1988 |
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Colony-Stimulating Factors; Doxorubicin; Drug Evaluation; Etoposide; Granulocyte Colony-Stimulating Factor; Hemoglobins; Humans; Ifosfamide; Leukocyte Count; Lung Neoplasms; Mesna; Neutrophils; Platelet Count; Recombinant Proteins | 1988 |
Phase II trial with high-dose ifosfamide and mesna given in a 24-h infusion for advanced GI tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Gastrointestinal Neoplasms; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; Middle Aged | 1989 |
Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988.
Topics: Adolescent; Child; Child, Preschool; Drug Evaluation; Humans; Ifosfamide; Infant; Mercaptoethanol; Mesna; Neoplasms; Remission Induction; Sarcoma | 1989 |
Ifosfamide, methotrexate, and 5-fluorouracil in advanced pretreated breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; Humans; Ifosfamide; Menopause; Mesna; Methotrexate; Middle Aged; Neoplasm Metastasis; Remission Induction; Time Factors | 1989 |
Severe renal failure following high-dose ifosfamide and mesna.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma; Dose-Response Relationship, Drug; Female; Humans; Ifosfamide; Kidney; Mercaptoethanol; Mesna; Middle Aged; Ovarian Neoplasms | 1989 |
Mesna: continuous or bolus infusion?
Topics: Drug Administration Schedule; Humans; Ifosfamide; Infusions, Intravenous; Injections, Intravenous; Mercaptoethanol; Mesna; Sarcoma; Soft Tissue Neoplasms | 1989 |
Phase II study of ifosfamide-etoposide-mesna in adults with advanced nonosseous sarcomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Etoposide; Female; Humans; Ifosfamide; Male; Mesna; Middle Aged; Remission Induction; Sarcoma | 1989 |
Ifosfamide in advanced carcinoma of the esophagus: a phase II trial with severe toxicity.
Topics: Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Evaluation; Esophageal Neoplasms; Female; Humans; Ifosfamide; Male; Mesna; Middle Aged | 1989 |
A phase II trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluation; Female; Humans; Ifosfamide; Male; Mesna; Mesothelioma; Middle Aged; Pleural Neoplasms | 1989 |
Chemotherapy induced emesis may exacerbate the nephrotoxicity of combined ifosfamide/mesna and cisplatin chemotherapy.
Topics: Acute Kidney Injury; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Ifosfamide; Male; Mesna; Vomiting | 1989 |
Phase II study of ifosfamide as a single drug for relapsed paediatric patients.
Topics: Adolescent; Child; Child, Preschool; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Ifosfamide; Male; Mesna; Neoplasm Recurrence, Local; Remission Induction; Time Factors | 1989 |
Alkylating activity in serum, urine, and CSF following high-dose ifosfamide in children.
Topics: Adolescent; Alkylation; Child; Child, Preschool; Colorimetry; Drug Evaluation; Drug Therapy, Combination; Half-Life; Humans; Ifosfamide; Infusions, Intravenous; Mesna; Neoplasms; Time Factors | 1989 |
Ifosfamide in pediatric malignant solid tumors.
Topics: Adolescent; Child; Child, Preschool; Drug Evaluation; Drug Therapy, Combination; Humans; Ifosfamide; Infant; Infusions, Intravenous; Mesna; Neoplasms; Remission Induction; Time Factors | 1989 |
High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma.
Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; Neoplasm Recurrence, Local; Sarcoma, Ewing; Vincristine | 1989 |
Toxicity of high-dose ifosfamide in children.
Topics: Adolescent; Bone Marrow; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Ifosfamide; Infant; Infusions, Intravenous; Kidney; Male; Mesna; Neoplasms; Nervous System; Time Factors | 1989 |
Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide. An experimental study/short communication.
Topics: Acetaldehyde; Animals; Cyclophosphamide; Cystitis; Female; Hemorrhage; Ifosfamide; Male; Mesna; Rats; Rats, Inbred Strains | 1989 |
Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; Middle Aged; Neoplasms; Urologic Diseases | 1989 |
Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma. The Gastrointestinal Tumor Study Group.
Topics: Adult; Aged; Carcinoma; Drug Evaluation; Female; Hematuria; Humans; Ifosfamide; Male; Mesna; Nervous System Diseases; Pancreatic Neoplasms | 1989 |
Mesna excretion and ifosfamide nephrotoxicity in children.
Topics: Adolescent; Adult; Child; Child, Preschool; Creatinine; Female; Humans; Ifosfamide; Kidney Diseases; Male; Mercaptoethanol; Mesna; Neoplasms; Proteinuria | 1989 |
Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix. A Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Evaluation; Drugs, Investigational; Female; Humans; Ifosfamide; Mesna; Middle Aged; Recurrence; Uterine Cervical Neoplasms | 1989 |
Fatal encephalopathy with ifosfamide/mesna.
Topics: Brain Diseases; Child; Drug Therapy, Combination; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; Rhabdomyosarcoma | 1989 |
Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Female; Humans; Ifosfamide; Mercaptoethanol; Mesna; Middle Aged; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Ovarian Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms | 1989 |
Ifosfamide, mitomycin and radiotherapy in non-small-cell lung cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Evaluation; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Mitomycins; Nausea; Remission Induction; Vomiting | 1989 |
A phase II study of ifosfamide in the treatment of relapses in Wilms' tumor.
Topics: Adolescent; Adult; Child; Child, Preschool; Drug Evaluation; Drug Therapy, Combination; Humans; Ifosfamide; Infant; Kidney Neoplasms; Mesna; Neoplasm Recurrence, Local; Remission Induction; Time Factors; Wilms Tumor | 1989 |
Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Humans; Ifosfamide; Leukocyte Count; Mesna; Middle Aged; Neoplasms, Germ Cell and Embryonal; Platelet Count; Time Factors; Uterine Neoplasms | 1989 |
Ifosfamide and mesna.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cystitis; Hemorrhage; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; Neoplasms, Germ Cell and Embryonal; Testicular Neoplasms | 1989 |
Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Half-Life; Humans; Ifosfamide; Lung Neoplasms; Mesna; Middle Aged; Obesity; Time Factors; Tissue Distribution | 1989 |
Tubular nephrotoxicity during long-term ifosfamide and mesna therapy.
Topics: Acetylglucosaminidase; Aminopeptidases; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; CD13 Antigens; Creatinine; Dose-Response Relationship, Drug; Drug Evaluation; Humans; Ifosfamide; Infusions, Intravenous; Injections, Intravenous; Kidney Tubules; Mesna; Proteinuria; Time Factors | 1989 |
Ifosfamide, etoposide, and thoracic irradiation therapy in 163 patients with unresectable small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Etoposide; Evaluation Studies as Topic; Female; Humans; Ifosfamide; Lorazepam; Lung Neoplasms; Male; Mesna; Metoclopramide; Middle Aged | 1987 |
The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16-213, doxorubicin and vincristine (VPAV) for small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Doxorubicin; Drug Resistance; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Vincristine | 1988 |
Phase II study of high dose ifosfamide plus mesna in inoperable non small cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged | 1988 |
Concurrent chemo-radiotherapy in small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Small Cell; Carmustine; Combined Modality Therapy; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged | 1988 |
Encephalopathy associated with ifosphamide/mesna therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Cyclophosphamide; Female; Humans; Ifosfamide; Mercaptoethanol; Mesna; Uterine Neoplasms | 1985 |
Ifosfamide/mesa and encephalopathy.
Topics: Brain Diseases; Carcinoma, Small Cell; Cyclophosphamide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mercaptoethanol; Mesna; Middle Aged; Sarcoma | 1985 |
Ifosfamide, mesna, and encephalopathy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Child; Cyclophosphamide; Female; Humans; Ifosfamide; Mercaptoethanol; Mesna | 1985 |
Avoiding ifosfamide/mesna encephalopathy.
Topics: Adolescent; Adult; Aged; Brain Diseases; Drug Therapy, Combination; Female; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; Middle Aged; Probability | 1986 |
Ifosfamide/mesna nomogram and serum albumin.
Topics: Drug Therapy, Combination; Female; Humans; Ifosfamide; Mercaptoethanol; Mesna; Pelvic Inflammatory Disease; Serum Albumin | 1986 |
Ifosfamide/mesna nomogram and serum albumin.
Topics: Humans; Ifosfamide; Mercaptoethanol; Mesna; Methods; Serum Albumin | 1986 |
Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna.
Topics: Acetylglucosaminidase; Adolescent; Adult; Aminopeptidases; CD13 Antigens; Child; Child, Preschool; Creatinine; Drug Evaluation; Female; Humans; Ifosfamide; Kidney Diseases; Kidney Tubules; Male; Mercaptoethanol; Mesna; Proteinuria | 1987 |
Encephalopathy with rapid infusion ifosfamide/mesna.
Topics: Brain Diseases; Drug Therapy, Combination; Humans; Ifosfamide; Infusions, Intravenous; Mercaptoethanol; Mesna | 1987 |
Ifosfamide/mesna encephalopathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Epilepsy, Tonic-Clonic; Female; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; Middle Aged; Psychoses, Substance-Induced | 1987 |
Fatal hypokalaemia associated with ifosfamide/mesna chemotherapy.
Topics: Drug Therapy, Combination; Humans; Hypokalemia; Ifosfamide; Male; Mercaptoethanol; Mesna | 1988 |
Identification and quantification of metabolite conjugates of activated cyclophosphamide and ifosfamide with mesna in urine by ion-pair extraction and fast atom bombardment mass spectrometry.
Topics: Acrolein; Animals; Cyclophosphamide; Ifosfamide; Kinetics; Mass Spectrometry; Mercaptoethanol; Mesna; Rats; Rats, Inbred Strains | 1985 |
[Encephalopathy caused by an ifosfamide-mesna combination].
Topics: Adult; Brain Diseases; Drug Therapy, Combination; Female; Humans; Ifosfamide; Mercaptoethanol; Mesna; Middle Aged | 1988 |
[Therapy of primary resistant or recurrent small cell bronchial carcinoma with vindesine and ifosfamide].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Drug Administration Schedule; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Neoplasm Recurrence, Local; Vindesine | 1986 |
Ifosfamide by bolus as treatment for advanced non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Small Cell; Drug Administration Schedule; Female; Humans; Ifosfamide; Injections, Intravenous; Lung Neoplasms; Male; Mesna; Middle Aged | 1986 |
Combination chemotherapy with ifosfamide, mitomycin, and cisplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Evaluation; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Mitomycins; Remission Induction | 1987 |
False-positive ketonuria during ifosfamide and mesna therapy.
Topics: False Positive Reactions; Female; Humans; Ifosfamide; Ketone Bodies; Lung Neoplasms; Male; Mercaptoethanol; Mesna; Middle Aged | 1986 |
Phase II study of ifosfamide in cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Central Nervous System Diseases; Drug Evaluation; Female; Hematologic Diseases; Humans; Ifosfamide; Lung Neoplasms; Mesna; Middle Aged; Nausea; Neoplasm Recurrence, Local; Uterine Cervical Neoplasms | 1986 |
Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases; Child; Child, Preschool; Electroencephalography; Female; Humans; Ifosfamide; Male; Mesna; Neoplasms; Seizures | 1986 |
Prediction of ifosfamide/mesna associated encephalopathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Electroencephalography; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mercaptoethanol; Mesna; Soft Tissue Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms | 1986 |
CNS-side effects induced by Ifosfamide-Mesna in children with osteosarcomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Central Nervous System Diseases; Child; Female; Humans; Ifosfamide; Mesna; Osteosarcoma | 1986 |
Phase II trial of ifosfamide in children with malignant solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Drug Evaluation; Female; Hematologic Diseases; Humans; Ifosfamide; Infant; Lymphoma; Male; Mesna; Neoplasms; Nervous System Diseases; Neurilemmoma; Osteosarcoma; Urologic Diseases | 1987 |
Recent experience with ifosfamide/mesna in solid tumors. International satellite symposium to the 3rd European Conference on Clinical Oncology. Stockholm, June 1985. Proceedings.
Topics: Humans; Ifosfamide; Mercaptoethanol; Mesna; Neoplasms | 1986 |
Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Doxorubicin; Female; Humans; Ifosfamide; Kidney Diseases; Leukopenia; Male; Mesna; Middle Aged; Nausea; Sarcoma; Soft Tissue Neoplasms; Vomiting | 1986 |
High-dose ifosfamide alone and in combination for solid malignancies in childhood.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Humans; Ifosfamide; Mesna; Nausea; Osteosarcoma | 1986 |
Treatment of advanced soft tissue and osteogenic sarcomas with continuous infusion of ifosfamide and mesna.
Topics: Female; Humans; Ifosfamide; Infusions, Intravenous; Male; Mercaptoethanol; Mesna; Middle Aged; Osteosarcoma; Soft Tissue Neoplasms | 1986 |
Ifosfamide in advanced pancreatic cancer. A 5-year experience.
Topics: Adult; Alopecia; Anemia; Drug Evaluation; Female; Humans; Ifosfamide; Leukopenia; Male; Mesna; Middle Aged; Pancreatic Neoplasms | 1986 |
The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
Topics: Adolescent; Adult; Child; Child, Preschool; Cyclophosphamide; Cystitis; Female; Hematuria; Hemorrhage; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; Neoplasms | 1987 |
Prevention of urotoxic side effects by regional detoxification with increased selectivity of oxazaphosphorine cytostatics.
Topics: Animals; Biotransformation; Cyclophosphamide; DNA; Glutathione; Ifosfamide; Kidney; Leukemia, Experimental; Mercaptoethanol; Mesna; Rats; Structure-Activity Relationship; Urinary Bladder; Urinary Bladder Neoplasms | 1986 |
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child; Combined Modality Therapy; Cystitis; Drug Evaluation; Etoposide; Humans; Ifosfamide; Mesna; Neoplasm Recurrence, Local; Sarcoma | 1987 |
Irreversible encephalopathy with ifosfamide/mesna.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Child, Preschool; Dactinomycin; Female; Humans; Ifosfamide; Maxillary Neoplasms; Mercaptoethanol; Mesna; Rhabdomyosarcoma; Vincristine | 1987 |
Phase II trial of ifosfamide/mesna in metastatic adult renal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diagnosis-Related Groups; Drug Evaluation; Female; Humans; Ifosfamide; Kidney Neoplasms; Male; Mercaptoethanol; Mesna; Middle Aged | 1987 |
Ifosfamide/mesna and hematuria.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Hematuria; Humans; Ifosfamide; Infant; Mercaptoethanol; Mesna | 1987 |
A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Doxorubicin; Drug Evaluation; Female; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; Middle Aged; Sarcoma; Soft Tissue Neoplasms | 1988 |
Treatment of advanced malignancies with ifosfamide under protection with mesna.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfamide; Male; Mesna; Middle Aged; Neoplasm Metastasis; Neoplasms | 1988 |
Malignant pleural mesothelioma: phase II pilot study of ifosfamide and mesna.
Topics: Adolescent; Adult; Aged; Drug Evaluation; Female; Humans; Ifosfamide; Kidney Diseases; Male; Mercaptoethanol; Mesna; Mesothelioma; Middle Aged; Pleural Neoplasms | 1988 |
Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study 8552.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Evaluation; Hematologic Diseases; Hematuria; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Mercaptoethanol; Mesna; Middle Aged | 1988 |
Ifosfamide/mesna related encephalopathy: a case report with a possible role of phenobarbital in enhancing neurotoxicity.
Topics: Adolescent; Brain Diseases; Drug Interactions; Drug Therapy, Combination; Epilepsy; Female; Humans; Ifosfamide; Mercaptoethanol; Mesna; Phenobarbital | 1988 |
Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin. A VIhP regimen.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cisplatin; Etoposide; Evaluation Studies as Topic; Humans; Ifosfamide; Kidney Diseases; Leukopenia; Male; Mesna; Mesonephroma; Nausea; Sepsis; Teratoma; Testicular Neoplasms | 1988 |
Treatment of gynecological adenocarcinomas with a combination of ifosfamide, adriamycin and cisplatin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Evaluation; Female; Genital Neoplasms, Female; Humans; Ifosfamide; Leukopenia; Mesna; Middle Aged; Remission Induction | 1988 |
Ifosfamide and Mesna in advanced malignancies.
Topics: Adult; Aged; Carcinoma, Bronchogenic; Female; Hematuria; Humans; Ifosfamide; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Mercaptoethanol; Mesna; Middle Aged; Neoplasms; Ovarian Neoplasms; Testicular Neoplasms | 1988 |
Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Ifosfamide; Mercaptoethanol; Mesna; Middle Aged | 1988 |
Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cystitis; Drug Evaluation; Female; Humans; Ifosfamide; Male; Mesna; Middle Aged; Sarcoma; Soft Tissue Neoplasms | 1985 |
Infusion of ifosphamide plus mesna.
Topics: Cyclophosphamide; Drug Interactions; Humans; Ifosfamide; Infusions, Parenteral; Mercaptoethanol; Mesna; Urinary Bladder Neoplasms | 1984 |
Infusion of ifosfamide plus mesna.
Topics: Cyclophosphamide; Drug Combinations; Drug Stability; Drug Storage; Humans; Ifosfamide; Infusions, Parenteral; Mercaptoethanol; Mesna | 1984 |
Proceedings of a symposium on ifosfamide (Mitoxana; Holoxan) and Mesna (Uromitexan). Coventry, U.K., 16-18 March 1983.
Topics: Animals; Cyclophosphamide; Humans; Ifosfamide; Mercaptoethanol; Mesna; Neoplasms | 1983 |
Combination chemotherapy with adriamycin, ifosfamide and mesna in extensive-stage non-small cell bronchogenic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Cyclophosphamide; Doxorubicin; Humans; Ifosfamide; Lung Neoplasms; Mercaptoethanol; Mesna | 1983 |
High-dose ifosfamide by infusion with mesna in advanced soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Female; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; Middle Aged; Sarcoma; Soft Tissue Neoplasms | 1983 |
Ifosfamide, mesna and vincristine in paediatric oncology.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Humans; Ifosfamide; Infant; Mercaptoethanol; Mesna; Neoplasms; Vincristine | 1983 |
High-dose ifosfamide and mesna as continuous infusion over five days--a phase I/II trial.
Topics: Cyclophosphamide; Drug Evaluation; Humans; Ifosfamide; Mercaptoethanol; Mesna; Neoplasms | 1983 |
Therapeutic effects of single-push or fractionated injections of cyclophosphamide or ifosfamide combined with mesna.
Topics: Animals; Cyclophosphamide; Drug Therapy, Combination; Ifosfamide; Male; Mercaptoethanol; Mesna; Mice; Mice, Inbred Strains; Neoplasms, Experimental | 1983 |
Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients.
Topics: Cyclophosphamide; Drug Evaluation; Drug Interactions; Female; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; Neoplasms; Testicular Neoplasms; Urinary Tract | 1983 |
High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma.
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Ifosfamide; Kidney; Male; Mercaptoethanol; Mesna; Middle Aged; Sarcoma; Soft Tissue Neoplasms | 1983 |
Failure of 2-mercaptoethane sulphonate sodium (mesna) to protect against ifosfamide nephrotoxicity.
Topics: Adult; Cyclophosphamide; Fanconi Syndrome; Female; Humans; Ifosfamide; Intestinal Neoplasms; Leiomyosarcoma; Mercaptoethanol; Mesna | 1984 |
Sodium-2-mercaptoethanesulfonate (MESNA) and ifosfamide nephrotoxicity.
Topics: Cyclophosphamide; Humans; Ifosfamide; Infusions, Parenteral; Kidney Diseases; Mercaptoethanol; Mesna | 1984 |
Bioavailability of orally administered mesna.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Biological Availability; Cyclophosphamide; Humans; Ifosfamide; Injections, Intravenous; Male; Mercaptoethanol; Mesna | 1984 |
The development of mesna for the inhibition of urotoxic side effects of cyclophosphamide, ifosfamide, and other oxazaphosphorine cytostatics.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Cystitis; Erythrocyte Count; Ifosfamide; Mercaptoethanol; Mesna; Rats; Urologic Diseases | 1980 |
Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds.
Topics: Animals; Cyclophosphamide; Cystitis; Female; Ifosfamide; Kidney; Mercaptoethanol; Mesna; Rats; Urinary Bladder | 1981 |
[Prevention of urotoxic actions of cyclophosphamide and ifosfamide by dimesna (preliminary communication) (author's transl)].
Topics: Animals; Cyclophosphamide; Ifosfamide; Kidney Diseases; Mercaptoethanol; Mesna; Oxidation-Reduction; Rats; Rats, Inbred Strains | 1982 |
Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment.
Topics: Adult; Aged; Cyclophosphamide; Female; Humans; Ifosfamide; Kidney Diseases; Leukopenia; Male; Mercaptoethanol; Mesna; Middle Aged; Neoplasms; Urinary Bladder Diseases | 1982 |
Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna).
Topics: Animals; Cyclophosphamide; Dogs; Drug Interactions; Female; Ifosfamide; Kinetics; Lethal Dose 50; Male; Mercaptoethanol; Mesna; Mice; Neoplasms, Experimental; Proscillaridin; Rats; Urinary Bladder Diseases | 1982 |
Mesna/ifosfamide, mitoxantrone, etoposide, bleomycin, vincristine, prednisone (MINE-BOP) combination chemotherapy in the treatment of refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematuria; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Mitoxantrone; Neutropenia; Prednisone; Prospective Studies; Recurrence; Survival Rate; Vincristine | 1995 |
Second-line treatment with ifosfamide and carboplatin in patients with ovarian carcinoma relapsing after treatment with carboplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Ifosfamide; Mesna; Middle Aged; Ovarian Neoplasms; Palliative Care | 1994 |
Dithio-bis-mercaptoethanesulphonate (DIMESNA) does not prevent cellular damage by metabolites of ifosfamide and cyclophosphamide in LLC-PK1 cells.
Topics: Animals; Cell Line; Cells, Cultured; Cyclophosphamide; DNA; DNA Replication; Drug Combinations; Ifosfamide; Kidney Tubules; Mesna; RNA; Thymidine; Uridine | 1994 |
Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow Transplantation; Breast Neoplasms; Carboplatin; Clinical Protocols; Drug Resistance; Etoposide; Genetic Vectors; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Ifosfamide; Informed Consent; Interleukin-3; Interleukin-6; Mesna; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancytopenia; Recombinant Fusion Proteins; Recombinant Proteins; Retroviridae; Stem Cell Factor; Transplantation, Autologous; Vinblastine | 1994 |
Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Enzyme-Linked Immunosorbent Assay; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Interleukin-10; Life Tables; Lymphoma, Large B-Cell, Diffuse; Male; Mesna; Methotrexate; Methylprednisolone Hemisuccinate; Middle Aged; Mitoxantrone; Neoplasm Proteins; Prognosis; Risk Factors; Sensitivity and Specificity; Severity of Illness Index; Survival Analysis; Treatment Outcome; Vincristine | 1995 |
Stability of ifosfamide in solutions for multiday infusion by external pump.
Topics: Antineoplastic Agents, Alkylating; Chromatography, High Pressure Liquid; Drug Stability; Ifosfamide; Infusion Pumps; Mesna; Solutions; Time Factors | 1995 |
Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Methylprednisolone; Middle Aged; Mitoxantrone; Prednisolone; Prospective Studies; Recurrence; Salvage Therapy; Vincristine | 1995 |
Mesna, doxorubicin, ifosfamide, and dacarbazine chemotherapy for ovarian mixed müllerian sarcoma: report of four cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Combined Modality Therapy; Dacarbazine; Doxorubicin; Female; Humans; Ifosfamide; Mesna; Middle Aged; Mixed Tumor, Mullerian; Ovarian Neoplasms; Sarcoma; Treatment Outcome | 1995 |
Differential effects of ifosfamide on the capacity of cytotoxic T lymphocytes and natural killer cells to lyse their target cells correlate with intracellular glutathione levels.
Topics: Antibodies, Monoclonal; Antigens, CD; Buthionine Sulfoximine; CD3 Complex; Cells, Cultured; Cytotoxicity, Immunologic; Glutathione; Humans; Ifosfamide; Interleukin-2; Intracellular Fluid; Killer Cells, Natural; Lymphocyte Activation; Mesna; Methionine Sulfoximine; T-Lymphocytes, Cytotoxic | 1995 |
Ifosfamide and etoposide in recurrent childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Etoposide; Female; Humans; Ifosfamide; Infant; Male; Mesna; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence | 1995 |
[Epileptic seizures and treatment with ifosfamide-mesna].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Epilepsy; Fatal Outcome; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Seizures | 1994 |
[Peri-operative chemotherapy during resection of pulmonary metastases of sarcoma].
Topics: Adult; Combined Modality Therapy; Female; Humans; Ifosfamide; Infusions, Intravenous; Intraoperative Period; Lung Neoplasms; Male; Mesna; Ondansetron; Prospective Studies; Sarcoma; Survival Analysis | 1994 |
Ifosfamide induced depletion of glutathione in human peripheral blood lymphocytes and protection by mesna.
Topics: Acetaldehyde; Acrolein; Animals; CHO Cells; Cricetinae; Glutathione; Humans; Ifosfamide; Intracellular Fluid; Lymphocytes; Mesna | 1994 |
Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Cysteine; Female; Glutathione; Homeostasis; Homocysteine; Humans; Ifosfamide; Infusions, Intravenous; Male; Mesna; Middle Aged; Sarcoma | 1994 |
MINE-ESHAP salvage therapy for recurrent and refractory lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Humans; Ifosfamide; Lymphoma; Mesna; Methylprednisolone Hemisuccinate; Mitoxantrone; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate | 1994 |
Direct detection of the intracellular formation of carboxyphosphamides using nuclear magnetic resonance spectroscopy.
Topics: Acrolein; Cell Death; Cyclophosphamide; Free Radical Scavengers; Half-Life; Humans; Ifosfamide; Magnetic Resonance Spectroscopy; Mesna; Perfusion; Phosphoramide Mustards; Phosphorus Isotopes; Sulfhydryl Compounds; Tumor Cells, Cultured | 1994 |
The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Screening Assays, Antitumor; Humans; Ifosfamide; Male; Mesna; Mice; Mice, Nude; Neoplasm Transplantation; Testicular Neoplasms; Tumor Cells, Cultured | 1994 |
Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; DNA Mutational Analysis; DNA Primers; Doxorubicin; Exons; Follow-Up Studies; Gene Deletion; Genes, DCC; Genes, p53; Humans; Ifosfamide; Immunohistochemistry; Leiomyosarcoma; Male; Mesna; Middle Aged; Molecular Sequence Data; Neoplasm Proteins; Neoplasm Staging; Nuclear Proteins; Point Mutation; Polymerase Chain Reaction; Polymorphism, Genetic; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Survival Analysis; Tumor Suppressor Protein p53 | 1994 |
Ifosfamide induced stress response in human lymphocytes.
Topics: Blotting, Western; Cells, Cultured; DNA; Glutathione; Heat-Shock Proteins; Humans; Ifosfamide; Interleukin-2; Isoelectric Focusing; Kinetics; Lymphocyte Activation; Lymphocytes; Mesna; Recombinant Proteins; Stress, Physiological; Thymidine | 1993 |
High dose ifosfamide with mesna uroprotection.
Topics: Drug Therapy, Combination; Humans; Ifosfamide; Lymphoma; Mesna; Urologic Diseases | 1993 |
[Soft tissue tumors: indications and results of hyperthermia].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Ifosfamide; Male; Mesna; Middle Aged; Neoplasm Recurrence, Local; Soft Tissue Neoplasms; Survival Rate | 1993 |
An unusual case of haematuria.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Hematuria; Humans; Ifosfamide; Male; Mesna; Quadriplegia; Urinary Bladder Neoplasms | 1993 |
In vitro studies on interaction of 4-hydroperoxyifosfamide and 2-mercaptoethanesulphonate in malignant gliomas.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Interactions; Drug Screening Assays, Antitumor; Glioma; Humans; Ifosfamide; Mesna; Models, Biological; Tumor Cells, Cultured | 1993 |
Ifosfamide combination regimens for soft-tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Male; Mesna; Middle Aged; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome; Urologic Diseases | 1993 |
Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Infusions, Intravenous; Male; Mesna; Middle Aged; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome; Urologic Diseases | 1993 |
Dramatic response to ifosfamide, mesna and doxorubicin chemotherapy regimen in an adult with clear cell sarcoma of the kidney.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Ifosfamide; Kidney Neoplasms; Mesna; Neoplasms, Germ Cell and Embryonal; Radiotherapy, Adjuvant | 1996 |
High-dose ifosfamide by infusion with Mesna in advanced refractory sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Doxorubicin; Female; Humans; Ifosfamide; Male; Mesna; Middle Aged; Pilot Projects; Sarcoma | 1996 |
Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents, Alkylating; Cystitis; Hemorrhage; Humans; Ifosfamide; Injections, Intravenous; Injections, Subcutaneous; Mesna; Safety; Urinary Tract; Vomiting | 1996 |
Successful treatment of a primary cardiac leiomyosarcoma with ifosfamide and etoposide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Etoposide; Follow-Up Studies; Heart Neoplasms; Humans; Ifosfamide; Infant; Leiomyosarcoma; Mesna; Microscopy, Electron; Time Factors | 1996 |
Response of small cell carcinoma of pancreas to a small cell lung cancer regimen: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Duodenal Neoplasms; Fatal Outcome; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Pancreatic Neoplasms; Radiotherapy Dosage; Tomography, X-Ray Computed; Vincristine | 1996 |
Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Germinoma; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Male; Mediastinal Neoplasms; Mesna; Middle Aged; Ovarian Neoplasms; Pilot Projects; Retroperitoneal Neoplasms; Testicular Neoplasms | 1996 |
Development of a canine chemotherapeutic model with ifosfamide.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood Platelets; Bone Neoplasms; Dogs; Drug Administration Schedule; Erythrocyte Count; Fever; Ifosfamide; Leukopenia; Male; Mesna; Survival Rate | 1996 |
Influence of mesna on urotoxic effects of selected bromosubstituted analogs of ifosfamide.
Topics: Administration, Oral; Animals; Cystitis; Edema; Female; Hemorrhage; Ifosfamide; Injections, Intraperitoneal; Lethal Dose 50; Maximum Allowable Concentration; Mesna; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Necrosis; Stereoisomerism; Urinary Bladder | 1997 |
Nephrotoxicity of ifosfamide--moving towards understanding the molecular mechanisms.
Topics: Animals; Antineoplastic Agents, Alkylating; Cyclophosphamide; DNA; Fanconi Syndrome; Humans; Ifosfamide; Immunosuppressive Agents; Kidney Tubules, Proximal; Mesna; Rats | 1997 |
Ifosfamide-based chemotherapy for recurrent or metastatic hemangiopericytoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Etoposide; Female; Forearm; Hemangiopericytoma; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Neoplasm Recurrence, Local; Salvage Therapy; Thoracic Neoplasms | 1997 |
Combined intravenous and oral mesna in outpatients treated with ifosfamide.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Agents, Alkylating; Cystitis; Female; Hemorrhage; Humans; Ifosfamide; Infusions, Intravenous; Male; Mesna; Middle Aged; Treatment Outcome; Urinary Bladder | 1997 |
Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Disease-Free Survival; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Life Tables; Lymphoma, Non-Hodgkin; Mesna; Methylprednisolone; Methylprednisolone Hemisuccinate; Mitoxantrone; Prognosis; Salvage Therapy; Texas; Treatment Outcome | 1997 |
Miliary osteosarcomatosis with associated hypocalcemia.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxorubicin; Expectorants; Fatal Outcome; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Hypocalcemia; Ifosfamide; Lung Neoplasms; Mesna; Osteosarcoma | 1997 |
[The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas].
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Drug Administration Schedule; Female; Histiocytoma, Benign Fibrous; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Osteosarcoma; Sarcoma; Sarcoma, Ewing; Soft Tissue Neoplasms | 1997 |
Administration of MINE protocol in untreated patients with intermediate and high grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Mitoxantrone; Remission Induction; Survival Rate; Treatment Outcome | 1997 |
Phase I trial of a 24-h continuous infusion of ifosfamide/mesna in acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Clinical Trials, Phase I as Topic; Drug Combinations; Humans; Ifosfamide; Infusions, Intravenous; Mesna; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Respiratory System Agents | 1996 |
The use of paediatric chemotherapy protocols at full dose is both a rational and feasible treatment strategy in adults with Ewing's family tumours.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Humans; Ifosfamide; Infusions, Intravenous; Injections, Intravenous; Male; Mesna; Middle Aged; Neuroectodermal Tumors, Primitive; Neutropenia; Sarcoma, Ewing; Vincristine | 1997 |
Inflammatory breast cancer: enhanced local control with hyperfractionated radiotherapy and infusional vincristine, ifosfamide and epirubicin.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Dose Fractionation, Radiation; Drug Administration Schedule; Epirubicin; Female; Humans; Ifosfamide; Infusion Pumps; Mesna; Neoplasm Staging; Survival Rate; Treatment Outcome; Vincristine | 1998 |
Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, Small Cell; Cyclophosphamide; Epirubicin; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Mesna; Prospective Studies; Recombinant Proteins; Vincristine | 1998 |
Effects of chemotherapy on osseointegration of implants: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Transplantation; Cisplatin; Dacarbazine; Dental Care for Chronically Ill; Dental Implantation, Endosseous; Dental Implants; Doxorubicin; Female; Fibula; Humans; Ifosfamide; Mandibular Neoplasms; Mesna; Osseointegration; Osteosarcoma | 1998 |
Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy.
Topics: Adult; Amino Acids; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Brain Diseases; Dicarboxylic Acids; Humans; Ifosfamide; Kidney Cortex; Kidney Diseases; Kidney Function Tests; Kidney Medulla; Magnetic Resonance Spectroscopy; Mesna; Methylene Blue; Molecular Weight; Neoplasms; Protons; Retinol-Binding Proteins; Urinalysis | 1997 |
Prolonged survival of stage IV malignant mixed Müllerian tumor of the ovary after carboplatin, mesna, ifosfamide, and cis-platin chemotherapy: case report.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Female; Humans; Ifosfamide; Mesna; Mice; Middle Aged; Mixed Tumor, Mullerian; Neoplasm Staging; Ovarian Neoplasms | 1998 |
Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Staging; Prognosis; Receptors, Estrogen; Recombinant Proteins; Tamoxifen; Treatment Outcome | 1999 |
Ifosfamide-induced stomatocytosis and mesna-induced echinocytosis: influence on biorheological properties of blood.
Topics: Adult; Anemia; Antineoplastic Agents, Alkylating; Cell Aggregation; Erythrocyte Deformability; Erythrocytes; Humans; Ifosfamide; In Vitro Techniques; Mesna; Microscopy, Electron, Scanning; Protective Agents; Rheology | 1999 |
Radiation therapy for consolidation of metastatic or recurrent sarcomas in children treated with intensive chemotherapy and stem cell rescue. A feasibility study.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Bone Neoplasms; Child; Cyclophosphamide; Dactinomycin; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Radiotherapy Dosage; Retrospective Studies; Salvage Therapy; Sarcoma; Treatment Failure; Vincristine; Whole-Body Irradiation | 1999 |
Management of cancer in pregnancy: a case of Ewing's sarcoma of the pelvis in the third trimester.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cesarean Section; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Ifosfamide; Infant, Newborn; Infusion Pumps, Implantable; Infusions, Intravenous; Magnetic Resonance Imaging; Mesna; Pelvic Bones; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy Trimester, Third; Prenatal Diagnosis; Sarcoma, Ewing; Ultrasonography, Prenatal | 1999 |
Unique alterations of thyroid function parameters after i.v. administration of alkylating drugs (cyclophosphamide and ifosfamide).
Topics: Adult; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Granulomatosis with Polyangiitis; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Mesna; Middle Aged; Prednisone; Recurrence; Scleritis; Thyroid Function Tests; Thyroid Gland; Thyroid Hormones; Thyrotropin; Thyroxine; Triiodothyronine; Triiodothyronine, Reverse | 1999 |
Toxicity of ifosfamide and its metabolite chloroacetaldehyde in cultured renal tubule cells.
Topics: Acetaldehyde; Adenosine Triphosphate; Animals; Antineoplastic Agents, Alkylating; Cell Division; Cells, Cultured; Glucose; Glutathione; Ifosfamide; Kidney Tubules, Proximal; Male; Mesna; Rabbits | 1999 |
RT-PCR evaluation of peripheral blood, bone marrow and peripheral blood stem cells in children and adolescents undergoing VACIME chemotherapy for Ewing's sarcoma and alveolar rhabdomyosarcoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Purging; Bone Neoplasms; Child; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 22; Combined Modality Therapy; Cyclophosphamide; DNA-Binding Proteins; Doxorubicin; Etoposide; Female; Forkhead Box Protein O1; Forkhead Transcription Factors; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Ifosfamide; Male; Mesna; Neoplasm Proteins; Neoplastic Cells, Circulating; Oncogene Proteins, Fusion; Paired Box Transcription Factors; PAX3 Transcription Factor; Proto-Oncogene Protein c-fli-1; Reverse Transcriptase Polymerase Chain Reaction; Rhabdomyosarcoma, Alveolar; RNA-Binding Protein EWS; Sarcoma, Ewing; Sensitivity and Specificity; Soft Tissue Neoplasms; Transcription Factors; Translocation, Genetic; Vincristine | 1999 |
A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Division; Cyclin A; Dacarbazine; Disease Progression; Doxorubicin; Female; Humans; Ifosfamide; Male; Mesna; Middle Aged; Prognosis; Prospective Studies; Sarcoma; Soft Tissue Neoplasms; Survival Analysis; Vincristine | 1999 |
Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fever; Follow-Up Studies; Humans; Ifosfamide; Infusions, Intravenous; Logistic Models; Male; Mesna; Middle Aged; Neutropenia; Protective Agents; Remission Induction; Sarcoma; Survival Rate | 2000 |
Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Female; Humans; Ifosfamide; Infusions, Intravenous; Leiomyosarcoma; Mesna; Middle Aged; Mixed Tumor, Mullerian; Neoplasm Staging; Protective Agents; Rhabdomyosarcoma; Sarcoma; Survival Analysis; Uterine Neoplasms | 2000 |
[Is it useful to perform a (67)gallium scintigraphy in the follow-up of patients with gastric lymphoma?].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Fatal Outcome; Follow-Up Studies; Gallium Radioisotopes; Gastrectomy; Gastroscopy; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Male; Mesna; Methylprednisolone; Mitoxantrone; Neoplasm Recurrence, Local; Paclitaxel; Prednisone; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy, Adjuvant; Stomach Neoplasms; Stomach Ulcer; Tomography, X-Ray Computed; Vincristine | 2001 |
Treatment of mandibular malignant fibrous histiocytoma during pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cesarean Section; Chemotherapy, Adjuvant; Dacarbazine; Doxorubicin; Female; Histiocytoma, Benign Fibrous; Humans; Ifosfamide; Mandibular Neoplasms; Mesna; Pregnancy; Pregnancy Complications, Neoplastic | 2001 |
[Post-operative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of German prospective randomised trial HIT'91].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Drug Administration Schedule; Etoposide; Germany; Humans; Ifosfamide; Lomustine; Medulloblastoma; Mesna; Nervous System Diseases; Neutropenia; Postoperative Period; Prospective Studies; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Treatment Outcome; Vincristine | 2001 |
Immunoglobulin D myeloma presenting as an extraosseous soft tissue tumor.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Humans; Ifosfamide; Immunoglobulin D; Immunoglobulin lambda-Chains; Magnetic Resonance Imaging; Male; Mesna; Multiple Myeloma; Shoulder; Soft Tissue Neoplasms | 2001 |
Serum creatine kinase levels parallel the clinical course for rhabdomyomatous Wilms tumor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Creatine Kinase; Dactinomycin; Disease Progression; Disease-Free Survival; Doxorubicin; Etoposide; Fatal Outcome; Female; Humans; Ifosfamide; Infant; Kidney Neoplasms; Mesna; Neoplasm Recurrence, Local; Nephrectomy; Reference Standards; Rhabdomyoma; Vincristine; Wilms Tumor | 2001 |
Postchemotherapy confusion.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Female; Humans; Ifosfamide; Mesna; Methylene Blue; Neurotoxicity Syndromes; Oncology Nursing; Osteosarcoma | 2001 |
[Malignant Brenner tumor and transitional cell ovarian carcinoma--description of two cases].
Topics: Antineoplastic Agents; Brenner Tumor; Carcinoma, Transitional Cell; Female; Humans; Ifosfamide; Mesna; Middle Aged; Ovarian Neoplasms | 2001 |
Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Infant; Male; Mesna; Neoplasm Metastasis; Remission Induction; Sarcoma; Sarcoma, Ewing; Soft Tissue Neoplasms; Treatment Outcome; Vincristine | 2002 |
U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bone Neoplasms; Cystitis; Diphosphonates; Drug Approval; Gastrointestinal Neoplasms; Hematuria; Hemorrhage; Humans; Ifosfamide; Imatinib Mesylate; Imidazoles; Mesna; Multiple Myeloma; Orphan Drug Production; Piperazines; Protective Agents; Pyrimidines; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Zoledronic Acid | 2002 |
High survival rate in childhood non-Hodgkin lymphoma without CNS involvement: results of BFM 95 study in Kuwait.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Infant; Kuwait; Leucovorin; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Mercaptopurine; Mesna; Methotrexate; Neoplasm Staging; Prednisolone; Prednisone; Survival Rate; Thioguanine; Treatment Outcome; Vincristine | 2003 |
Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Clinical Trials, Phase II as Topic; Data Interpretation, Statistical; Endpoint Determination; Head and Neck Neoplasms; Humans; Ifosfamide; Mesna; Neutropenia; Paclitaxel; Reproducibility of Results; Survival; Taxoids | 2003 |
Has "MAID" made it in the management of high-risk soft-tissue sarcoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Doxorubicin; Extremities; Humans; Ifosfamide; Mesna; Risk Factors; Sarcoma; Soft Tissue Neoplasms | 2003 |
Comparative toxicity of ifosfamide metabolites and protective effect of mesna and amifostine in cultured renal tubule cells.
Topics: Acetaldehyde; Acrolein; Amifostine; Animals; Antineoplastic Agents; Cells, Cultured; Dose-Response Relationship, Drug; Glucose; Glutathione; Ifosfamide; Kidney Tubules; Mesna; Neutral Red; Rabbits | 2003 |
Single center experience of a new intensive induction therapy for ewing's family of tumors: feasibility, toxicity, and stem cell mobilization properties.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Doxorubicin; Etoposide; Feasibility Studies; Female; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Male; Mesna; Neoplasm Staging; Sarcoma, Ewing; Treatment Outcome; Vincristine | 2003 |
Defining supervision and duties for the ward maid.
Topics: Dacarbazine; Hospital Administration; Hospitals; Humans; Ifosfamide; Mesna | 1955 |
[Epidermophytosis among workers of a copper mine in Southern Bulgaria].
Topics: Bulgaria; Copper; Humans; Ifosfamide; Mesna; Mining; Tinea | 1959 |
Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis.
Topics: Animals; Anti-Inflammatory Agents; Cystitis; Dexamethasone; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hemorrhage; Ifosfamide; Male; Mesna; Organ Size; Protective Agents; Rats; Rats, Wistar; Sodium Chloride; Treatment Outcome; Urinary Bladder | 2003 |
Extended total sacrectomy and reconstruction for sacral tumor.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Dacarbazine; Diagnostic Errors; Doxorubicin; Fibula; Follow-Up Studies; Humans; Ifosfamide; Ilium; Internal Fixators; Intervertebral Disc Displacement; Laminectomy; Lumbar Vertebrae; Male; Mesna; Neoadjuvant Therapy; Neoplasm Invasiveness; Radiotherapy, Adjuvant; Recovery of Function; Rhizotomy; Sacrum; Sarcoma; Spinal Neoplasms; Spinal Nerve Roots | 2004 |
Primary omental synovial sarcoma: a case with cytogenetic confirmation.
Topics: Adult; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Doxorubicin; Etoposide; Fatal Outcome; Female; Humans; Ifosfamide; Maternal Age; Mesna; Neoplasm Recurrence, Local; Omentum; Peritoneal Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy, High-Risk; Sarcoma, Synovial | 2004 |
Extraskeletal Ewing sarcoma of the diaphragm presenting with hemothorax.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Child; Combined Modality Therapy; Dacarbazine; Doxorubicin; Dyspnea; Female; Hemothorax; Humans; Ifosfamide; Mesna; Muscle Neoplasms; Neoplasm Invasiveness; Organ Specificity; Radiotherapy, Adjuvant; Remission Induction; Ribs; Sarcoma, Ewing | 2004 |
Mesna ameliorates intestinal mucosa damage after ifosfamide administration in the rabbit at a dose-related manner.
Topics: Animals; Apoptosis; Dose-Response Relationship, Drug; Ifosfamide; Intestinal Mucosa; Mesna; Rabbits | 2004 |
Aggressive mixed epithelial-stromal tumour of the kidney treated with chemotherapy and radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Doxorubicin; Epithelial Cells; Female; Humans; Ifosfamide; Kidney Neoplasms; Mesna; Middle Aged; Nephrectomy; Radiotherapy, Adjuvant; Stromal Cells | 2004 |
A rare case of breast sarcoma brain metastases.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Fatal Outcome; Female; Humans; Ifosfamide; Mesna; Phyllodes Tumor; Tomography, X-Ray Computed | 2005 |
The role of preoperative radiotherapy in nonmetastatic high-grade osteosarcoma of the extremities for limb-sparing surgery.
Topics: Adolescent; Adult; Aged; Amputation, Surgical; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Epirubicin; Extremities; Humans; Ifosfamide; Limb Salvage; Male; Mesna; Methotrexate; Middle Aged; Osteosarcoma; Prognosis; Radiotherapy Dosage; Retrospective Studies; Survival Rate | 2005 |
Acetaminophen-induced anion gap metabolic acidosis and 5-oxoprolinuria (pyroglutamic aciduria) acquired in hospital.
Topics: Acetaminophen; Acid-Base Equilibrium; Acidosis; Adult; Analgesics, Non-Narcotic; Antineoplastic Combined Chemotherapy Protocols; Bicarbonates; Candidiasis; Chlorides; Cytarabine; Etoposide; Fatal Outcome; Fever; Humans; Ifosfamide; Kidney Tubular Necrosis, Acute; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Mesna; Neutropenia; Polycystic Kidney, Autosomal Dominant; Pyrrolidonecarboxylic Acid; Salvage Therapy; Systemic Inflammatory Response Syndrome | 2005 |
Doxorubicin and ifosfamide-mesna in advanced and recurrent uterine sarcomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Protective Agents; Retrospective Studies; Sarcoma; Treatment Outcome; Uterine Neoplasms | 2005 |
Primary angiosarcoma of the ovary: a case report of Stage I disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Doxorubicin; Female; Hemangiosarcoma; Humans; Ifosfamide; Mesna; Neoplasm Staging; Ovarian Neoplasms | 2005 |
Alveolar soft part sarcoma: a rare and enigmatic entity.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Dacarbazine; Doxorubicin; Female; Humans; Ifosfamide; Male; Mesna; Neoplasm Metastasis; Neoplasm Staging; Sarcoma, Alveolar Soft Part; Soft Tissue Neoplasms; Survival Rate | 2005 |
Preoperative chemotherapy and split-course radiation therapy for patients with localized soft tissue sarcomas: home run, base hit, or strike out?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Doxorubicin; Humans; Ifosfamide; Mesna; Meta-Analysis as Topic; Neoadjuvant Therapy; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sarcoma; Survival Analysis; Treatment Failure; Treatment Outcome | 2006 |
Successful treatment via chemotherapy and surgical resection of a femoral hemangiopericytoma with pulmonary metastasis.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Doxorubicin; Femoral Neoplasms; Hemangiopericytoma; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
[A case of secondary malignant lymphoma of the urinary bladder].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Mesna; Middle Aged; Mitoxantrone; Prednisone; Urinary Bladder Neoplasms; Vincristine | 2006 |
Ifosfamide metabolites CAA, 4-OH-Ifo and Ifo-mustard reduce apical phosphate transport by changing NaPi-IIa in OK cells.
Topics: Acetaldehyde; Animals; Antineoplastic Agents, Alkylating; Biological Transport; Cell Death; Cell Line; Dose-Response Relationship, Drug; Gene Expression Regulation; Ifosfamide; Kidney; Mesna; Opossums; Phosphates; Phosphoramide Mustards; RNA, Messenger; Sodium-Phosphate Cotransporter Proteins, Type IIa | 2006 |
Synovial cell sarcoma of the vulva: multimodality treatment incorporating preoperative external-beam radiation, hemivulvectomy, flap reconstruction, interstitial brachytherapy, and chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Doxorubicin; Female; Humans; Ifosfamide; Mesna; Middle Aged; Plastic Surgery Procedures; Sarcoma, Synovial; Surgical Flaps; Vulvar Neoplasms | 2007 |
Ifosfamide toxicity in cultured proximal renal tubule cells.
Topics: Acetaldehyde; Acrolein; Amifostine; Animals; Cell Culture Techniques; Cells, Cultured; Dose-Response Relationship, Drug; Ifosfamide; Inulin; Ion Transport; Kidney Tubules, Proximal; Male; Mesna; p-Aminohippuric Acid; Protective Agents; Rabbits; Tetraethylammonium | 2007 |
Retroperitoneal synovial sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Humans; Ifosfamide; Male; Mast Cells; Mesna; Mitosis; Retroperitoneal Neoplasms; Sarcoma, Synovial; Thoracic Neoplasms | 2006 |
[Malignant fibrous histiocytoma of the retroperitoneum--review of clinical course and histopathology].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Drug Administration Schedule; Female; Histiocytoma, Malignant Fibrous; Humans; Ifosfamide; Male; Mesna; Middle Aged; Retroperitoneal Neoplasms | 2006 |
Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biliary Atresia; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunocompromised Host; Immunosuppressive Agents; Liver Transplantation; Lymphoma, T-Cell, Peripheral; Lymphoproliferative Disorders; Melphalan; Mesna; Postoperative Complications; Prednisone; Radiotherapy, Adjuvant; Transplantation, Autologous; Vidarabine; Vincristine | 2008 |
Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing family tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Neoadjuvant Therapy; Neuroectodermal Tumors, Primitive; Pelvic Bones; Peripheral Blood Stem Cell Transplantation; Remission Induction; Risk; Sarcoma, Ewing; Scapula; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2007 |
The effect of short-term intensive chemotherapy on reactivation of tuberculosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Methylprednisolone; Middle Aged; Mitoxantrone; Mycobacterium tuberculosis; Prednisone; Retrospective Studies; Tuberculosis; Vincristine; Virus Activation | 2007 |
Cyclooxygenase-2 expression on ifosfamide-induced hemorrhagic cystitis in rats.
Topics: Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cystitis; Drug Therapy, Combination; Etoricoxib; Hemorrhage; Ifosfamide; Immunoenzyme Techniques; Indomethacin; Male; Mesna; Pentoxifylline; Protective Agents; Pyridines; Rats; Rats, Wistar; Sulfones; Thalidomide | 2008 |
[Responses of 109 adult soft tissue sarcoma patients to chemotherapy].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Dacarbazine; Doxorubicin; Extremities; Female; Follow-Up Studies; Humans; Ifosfamide; Liver Neoplasms; Lung Neoplasms; Male; Mesna; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Palliative Care; Pelvic Neoplasms; Remission Induction; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Vincristine; Young Adult | 2007 |
Mediastinal sarcoma with deviated tracheal anatomy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Doxorubicin; Female; Humans; Ifosfamide; Immunohistochemistry; Mediastinal Neoplasms; Mesna; Middle Aged; Protective Agents; Radiography, Thoracic; Sarcoma; Tomography, X-Ray Computed; Trachea; Vimentin | 2008 |
Langerhans cell sarcoma emanating from the upper arm skin: successful treatment by MAID regimen.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arm; Dacarbazine; Doxorubicin; Humans; Ifosfamide; Langerhans Cell Sarcoma; Male; Mesna; Skin Neoplasms | 2008 |
Stage IV primitive-appearing sinus and orbital rhabdomyosarcoma presenting in a 68-year-old female previously treated for breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Dacarbazine; Doxorubicin; Female; Humans; Ifosfamide; Maxillary Sinus Neoplasms; Mesna; Orbital Neoplasms; Rhabdomyosarcoma | 2008 |
Metastatic malignant teratoma arising from mediastinal nonseminomatous germ cell tumor: a case report.
Topics: Adult; Dacarbazine; Doxorubicin; Fatal Outcome; Humans; Ifosfamide; Leukemia, Myeloid, Acute; Male; Mediastinal Neoplasms; Mesna; Neoplasms, Germ Cell and Embryonal; Teratoma | 2008 |
Undifferentiated sarcoma of the maxillary sinus: report of a rare case in an adult.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Fatal Outcome; Humans; Ifosfamide; Male; Maxillary Sinus Neoplasms; Mesna; Middle Aged; Protective Agents; Sarcoma; Vincristine | 2009 |
Long-lasting multiagent chemotherapy in adult high-risk Ewing's sarcoma of bone.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Mesna; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Remission Induction; Sarcoma, Ewing; Treatment Outcome; Young Adult | 2009 |
Hepatoblastoma presenting with focal nodular hyperplasia after treatment of neuroblastoma.
Topics: Adrenal Gland Neoplasms; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Fluorouracil; Focal Nodular Hyperplasia; Granulocyte Colony-Stimulating Factor; Hepatectomy; Hepatoblastoma; Humans; Ifosfamide; Immunoglobulin G; Incidental Findings; Liver Neoplasms; Male; Melphalan; Mesna; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Neuroblastoma; Radiotherapy, Adjuvant; Tomography, X-Ray Computed; Vincristine | 2008 |
Temporary remission of a multirecurrent cystosarcoma phyllodes of the breast by using continuous chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Recurrence, Local; Phyllodes Tumor; Protective Agents; Remission Induction | 2009 |
Chemotherapy for Langerhans cell sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Dacarbazine; Doxorubicin; Humans; Ifosfamide; Langerhans Cell Sarcoma; Mesna | 2009 |
Autologous stem cell transplant in a patient with Down syndrome and relapsed Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Child; Combined Modality Therapy; Cyclophosphamide; Down Syndrome; Doxorubicin; Etoposide; Granulocyte Colony-Stimulating Factor; Hodgkin Disease; Humans; Ifosfamide; Male; Mesna; Peripheral Blood Stem Cell Transplantation; Prednisone; Procarbazine; Recurrence; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Vinblastine; Vincristine; Vinorelbine | 2009 |
Successful treatment of metastatic malignant fibrous histiocytoma of the kidney.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemotherapy, Adjuvant; Dacarbazine; Doxorubicin; Histiocytoma, Malignant Fibrous; Humans; Ifosfamide; Kidney Neoplasms; Lung Neoplasms; Male; Mesna; Middle Aged; Nephrectomy; Thoracoscopy; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Continuously improving ifosfamide/mesna: a winning combination.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Humans; Ifosfamide; Mesna; Sarcoma | 2010 |
Cyclooxygenase-2 contributes to functional changes seen on experimental hemorrhagic cystitis induced by ifosfamide in rat urinary bladder.
Topics: Animals; Antineoplastic Agents, Alkylating; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cystitis; Dinoprostone; Disease Models, Animal; Hemorrhage; Ifosfamide; Inflammation; Male; Mesna; Muscle Contraction; Muscle, Smooth; Rats; Rats, Wistar; Severity of Illness Index; Urination | 2011 |
Two consecutive cases of platinum-refractory pulmonary pleomorphic carcinoma that showed dramatic responses to MAID (mesna, doxorubicin, ifosfamide and dacarbazine) chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Organoplatinum Compounds; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma.
Topics: Abdominal Neoplasms; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Etoposide; Female; Humans; Ifosfamide; Infant; Kaplan-Meier Estimate; Lomustine; Male; Melphalan; Mesna; Neuroblastoma; Pilot Projects; Risk Factors; Thoracic Neoplasms; Topotecan; Treatment Outcome | 2011 |
Neuroblastoma in an adult: case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Brain Neoplasms; Carboplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Mesna; Neuroblastoma; Spinal Cord Compression; Spinal Cord Neoplasms; Thoracic Vertebrae; Vincristine; Young Adult | 2010 |
Mesna, doxorubicin, ifosfamide and dacarbazine chemotherapy for uterine leiomyosarcoma: a report of two cases.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Female; Humans; Ifosfamide; Leiomyosarcoma; Mesna; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Uterine Neoplasms | 2011 |
[Nephropathy following administration of angiogenesis inhibitors].
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bowman Capsule; Dacarbazine; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Endothelium, Vascular; Fibrosarcoma; Gemcitabine; Glomerulonephritis, Membranoproliferative; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Muscle Neoplasms; Podocytes; Proteinuria; Taxoids; Vascular Endothelial Growth Factor A | 2011 |
Interleukin-4 modulates the inflammatory response in ifosfamide-induced hemorrhagic cystitis.
Topics: Animals; Cyclooxygenase 2; Cystitis; Hemorrhage; Ifosfamide; Interleukin-1beta; Interleukin-4; Male; Mesna; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide Synthase Type II; Tumor Necrosis Factor-alpha; Urinary Bladder | 2012 |
[Severe skin reaction with mucous membrane inflammation during MINE chemotherapy].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Drug Eruptions; Edema; Etoposide; Female; Glossitis; Hodgkin Disease; Humans; Hyperalgesia; Ifosfamide; Mesna; Mitoxantrone; Mucositis; Panniculitis | 2011 |
The effect of N-acetylcysteine on the antitumor activity of ifosfamide.
Topics: Acetylcysteine; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Humans; Ifosfamide; Mesna; Neuroblastoma; Phosphoramide Mustards; Rhabdomyosarcoma | 2011 |
Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
Topics: Adolescent; Age Factors; Anemia; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Doxorubicin; Epirubicin; Female; Humans; Ifosfamide; Incidence; Male; Mesna; Neutropenia; Rhabdomyosarcoma; Sex Characteristics; Survival Rate; Thrombocytopenia; Vincristine; Young Adult | 2012 |
Neoadjuvant and adjuvant chemotherapy with modified mesna, adriamycin, ifosfamide, and dacarbazine (MAID) regimen for adult high-grade non-small round cell soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Ifosfamide; Male; Mesna; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Sarcoma; Treatment Outcome | 2013 |
Successful treatment of ICE-rituximab chemotherapy and subsequent bone marrow transplantation in a patient with early-relapse Burkitt leukemia and inverted duplication of 1q.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Burkitt Lymphoma; Carboplatin; Child; Chromosome Duplication; Chromosomes, Human, Pair 1; Etoposide; Humans; Ifosfamide; Male; Mesna; Neoplasm Recurrence, Local; Rituximab | 2012 |
Adjuvant chemotherapy decreases and postpones distant metastasis in extremity stage IIB/III synovial sarcoma patients.
Topics: Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Extremities; Female; Gemcitabine; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Mesna; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Adjuvant; Remission Induction; Sarcoma, Synovial; Soft Tissue Neoplasms; Taxoids | 2012 |
[A case of mediastinal angiosarcoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chest Pain; Doxorubicin; Dyspnea; Female; Hemangiosarcoma; Humans; Ifosfamide; Magnetic Resonance Imaging; Mediastinal Neoplasms; Mesna; Neoadjuvant Therapy; Neoplasm Invasiveness; Positron-Emission Tomography; Radiotherapy, Adjuvant; Remission Induction; Tachycardia, Sinus; Tomography, X-Ray Computed; Weight Loss | 2012 |
[Long-term remission of Langerhans cell sarcoma by AIM regimen combined with involved-field irradiation].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Ifosfamide; Langerhans Cell Sarcoma; Mesna; Radiochemistry; Time Factors; Treatment Outcome | 2012 |
[Treatment and prognosis of stage IV alveolar soft part sarcoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Ifosfamide; Lower Extremity; Lung Neoplasms; Male; Mesna; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Particle Accelerators; Remission Induction; Salvage Therapy; Sarcoma, Alveolar Soft Part; Soft Tissue Neoplasms; Survival Rate | 2012 |
Physical and chemical stability of high-dose ifosfamide and mesna for prolonged 14-day continuous infusion.
Topics: Chemical Phenomena; Drug Combinations; Drug Stability; Drug Storage; Humans; Ifosfamide; Infusions, Intravenous; Mesna; Outpatients; Pharmaceutical Solutions | 2014 |
Neoadjuvant treatment with preoperative radiotherapy for extremity soft tissue sarcomas: long-term results from a single institution in Turkey.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Disease-Free Survival; Doxorubicin; Extremities; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Male; Mesna; Middle Aged; Preoperative Care; Protective Agents; Radiotherapy, Adjuvant; Retrospective Studies; Sarcoma; Treatment Outcome; Turkey; Young Adult | 2014 |
Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R-ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Combined Modality Therapy; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma; Male; Mesna; Middle Aged; Retrospective Studies; Rituximab; Salvage Therapy; Transplantation, Autologous; Young Adult | 2014 |
Expression of ERCC1 and TUBB3 in locally advanced cervical squamous cell cancer and its correlation with different therapeutic regimens.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase II as Topic; Disease Progression; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Gene Expression Regulation, Neoplastic; Humans; Hysterectomy; Ifosfamide; Kaplan-Meier Estimate; Mesna; Middle Aged; Neoplasm Proteins; Palliative Care; Prognosis; Radiotherapy, Adjuvant; Tubulin; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine | 2015 |
Chemotherapy for Uterine Carcinosarcoma with Carboplatin, Ifosfamide and Mesna.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Demography; Disease-Free Survival; Female; Humans; Ifosfamide; Mesna; Middle Aged; Retrospective Studies; Treatment Outcome; Uterine Neoplasms | 2015 |
Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinosarcoma; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Female; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Staging; Neutropenia; Protective Agents; Retrospective Studies; Treatment Outcome; Uterine Neoplasms | 2016 |
A retrospective study of treatment and prophylaxis of ifosfamide-induced hemorrhagic cystitis in pediatric and adolescent and young adult (AYA) patients with solid tumors.
Topics: Adolescent; Adult; Child; Child, Preschool; Cystitis; Drug Administration Schedule; Female; Hemorrhage; Humans; Ifosfamide; Incidence; Infant; Male; Mesna; Neoplasms; Protective Agents; Retrospective Studies; Risk Factors; Young Adult | 2016 |
Nasal Type Extranodal Natural Killer/T (NK/T) Cell Lymphoma Presenting as Periorbital Cellulitis: A Case Report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diagnosis, Differential; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lymphoma, Extranodal NK-T-Cell; Male; Mesna; Methotrexate; Orbital Cellulitis; Paranasal Sinus Neoplasms; Prognosis; Treatment Outcome | 2016 |
Pazopanib induced a partial response in a patient with metastatic fibrosarcomatous dermatofibrosarcoma protuberans without genetic translocations resistant to mesna, doxorubicin, ifosfamide and dacarbazine chemotherapy and gemcitabine-docetaxel chemothera
Topics: Abdomen; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Deoxycytidine; Dermatofibrosarcoma; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Fatal Outcome; Gemcitabine; Humans; Ifosfamide; Indazoles; Male; Mesna; Middle Aged; Pyrimidines; Skin Neoplasms; Sulfonamides | 2017 |
The risk of postoperative complications and functional impairment after multimodality treatment for limb and trunk wall soft-tissue sarcoma: Long term results from a monocentric series.
Topics: Abdominal Wall; Activities of Daily Living; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Dacarbazine; Doxorubicin; Extremities; Female; Follow-Up Studies; Humans; Ifosfamide; Male; Mesna; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Postoperative Complications; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Thoracic Wall; Torso; Tumor Burden; Young Adult | 2017 |
Primary Cardiac Leiomyosarcoma: A 27-Month Survival with Surgery and Chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Docetaxel; Doxorubicin; Fatal Outcome; Gemcitabine; Heart Neoplasms; Humans; Ifosfamide; Indoles; Leiomyosarcoma; Life Support Care; Male; Mesna; Pyrroles; Sunitinib; Taxoids | 2017 |
Establishment of a spontaneously transformed cell line (JU-PI) from a myxoinflammatory fibroblastic sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Transformed; Cell Proliferation; Dacarbazine; Doxorubicin; Fibrosarcoma; Humans; Ifosfamide; Karyotype; Male; Mesna; Neoplasm Recurrence, Local; Primary Cell Culture; Soft Tissue Neoplasms; Translocation, Genetic; Vincristine | 2018 |
Neutrophils contribute to the pathogenesis of hemorrhagic cystitis induced by ifosfamide.
Topics: Animals; Antineoplastic Agents, Alkylating; Cystitis; Drug Therapy, Combination; Female; Hemorrhage; Ifosfamide; Mesna; Mice; Neutrophil Infiltration; Polysaccharides; Protective Agents | 2018 |
Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma.
Topics: Adult; Aged; Dacarbazine; Doxorubicin; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Neoplasms, Complex and Mixed; Retrospective Studies; Sarcoma; Survival Analysis | 2018 |
MAID chemotherapy regimen as a treatment strategy for metastatic malignant ameloblastoma: A case report.
Topics: Adult; Ameloblastoma; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Doxorubicin; Female; Humans; Ifosfamide; Jaw Neoplasms; Lung Neoplasms; Mesna; Neoplasm Metastasis; Neoplasm Recurrence, Local; Treatment Outcome | 2019 |
Primary angiosarcoma of thyroid.
Topics: Antibiotics, Antineoplastic; Doxorubicin; Hemangiosarcoma; Humans; Ifosfamide; Male; Mesna; Middle Aged; Thyroid Gland; Thyroid Neoplasms; Ultrasonography | 2019 |
Neoadjuvant chemotherapy for primary sarcoma of the breast: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Doxorubicin; Female; Humans; Ifosfamide; Leiomyosarcoma; Lymph Node Excision; Mastectomy; Mesna; Middle Aged; Neoadjuvant Therapy; Protective Agents; Rare Diseases; Unilateral Breast Neoplasms | 2019 |
Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Ifosfamide; Male; Mesna; Middle Aged; Neoplasm Staging; Protective Agents; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome; Young Adult | 2020 |
Complete remission of a case of high-grade myxofibrosarcoma with lung metastases after modified MAID regimen chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Fibrosarcoma; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna | 2020 |
Excellent Tolerability of Ifosfamide and Mesna Via Continuous Infusion in a Pediatric Patient Population.
Topics: Child; Drug Administration Schedule; Humans; Ifosfamide; Infusions, Intravenous; Mesna; Neoplasms | 2022 |
Ifosfamide-induced acute kidney injury in a patient with leiomyosarcoma: A case report.
Topics: Acetylcysteine; Acute Kidney Injury; Creatinine; Female; Humans; Ifosfamide; Leiomyosarcoma; Mesna; Urea | 2022 |
High-dose continuous-infusion ifosfamide in advanced thymic epithelial Tumors: A TYME network study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Ifosfamide; Lung Neoplasms; Mesna; Progression-Free Survival; Prospective Studies | 2023 |
[8] and [10]-Gingerol reduces urothelial damage in ifosfamide-induced hemorrhagic cystitis via JAK/STAT/FOXO signaling pathway via IL-10.
Topics: Animals; Cystitis; Female; Hemorrhage; Ifosfamide; Inflammation; Interleukin-10; Mesna; Mice; Signal Transduction | 2023 |